[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 567
1. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


2. Gashi-Luci LH, Limani RA, Kurshumliu FI: Invasive ductal carcinoma within fibroadenoma: a case report. Cases J; 2009;2:174

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Fibroadenoma is the most common benign tumor of the female breast with the highest incidence before age 30.
  • CASE PRESENTATION: We present a rare case of a 39 years old female with invasive ductal carcinoma arising within fibroadenoma.
  • CONCLUSION: There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):244-6 [19574682.001]
  • [Cites] Pathol Int. 1994 Dec;44(12):874-7 [7866572.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):614-22 [1850948.001]
  • [Cites] Surg Gynecol Obstet. 1985 Feb;160(2):99-104 [2982218.001]
  • [Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):736-42 [11345838.001]
  • [Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]
  • [Cites] Cancer. 1975 Feb;35(2):450-6 [1111920.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):334-8 [15375712.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):795-7 [12354814.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):590-4 [6329129.001]
  • (PMID = 19946485.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783130
  •  go-up   go-down


3. Yang JX, Han YJ, Zheng H, Luo RC: [Expression of PAK4 in breast cancer and benign breast pathological changes]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):981-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].
  • OBJECTIVE: To study the role of p21-activated kinase-4 (PAK4) in the occurrence, progression and metastasis of breast cancer.
  • METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.
  • RESULTS: PAK4 was expressed mainly in the cytoplasm of the cancer cells, occasionally in the cell nuclei, and virtually not expressed in the matrix surrounding the breast cells.
  • PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.
  • CONCLUSION: PAK4 is closely correlated to the progression and metastasis of breast cancer and may become a new diagnostic and therapeutic target of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501374.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


Advertisement
4. Sandoval-Hermosillo F, Vázquez-Lara GA, Farias-Evangelista LD, Madrid-Venegas DC, Jiménez-Covarrubias MG, Ramírez-Villaseñor M, Delgado-Enciso I, Rodríguez-Hernández A, Montoya F, Montaño-Plasencia V, Vásquez C: [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico]. Rev Salud Publica (Bogota); 2010 Jun;12(3):446-53
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico].
  • [Transliterated title] Comparación de dos métodos diagnósticos en tumores mamarios en un Centro de Cancerología de Colima, México.
  • OBJECTIVE: Determining the relationship between mammography neoplasm reports and histopathological diagnosis of neoplasms.
  • Patients were included who were attending the state cancerology centre (Centro Estatal de Cancerología) in Colima, Mexico.
  • Inclusion parameters were: females having mammography and BIRADS score of 1 or over; females having biopsy and histopathology diagnosis; females of all ages, all clinic stages having a complete clinic record.
  • RESULTS: No relationship between a BIRADS score classified as being benign (BIRADS I-II-III) or malign (BIRADS IV-V) was found with histopathological results (benign or malign) (p=0.0666).
  • CONCLUSIONS: I, III and V BIRADS scores had a relationship with histopathological diagnosis, while category II and IV BIRADS scores had no relationship.
  • [MeSH-major] Biopsy / statistics & numerical data. Breast Neoplasms / diagnosis. Cancer Care Facilities. Mammography / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Female. Humans. Medical Records. Mexico. Middle Aged. Severity of Illness Index

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21311832.001).
  • [ISSN] 0124-0064
  • [Journal-full-title] Revista de salud pública (Bogotá, Colombia)
  • [ISO-abbreviation] Rev Salud Publica (Bogota)
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Colombia
  •  go-up   go-down


5. Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J: The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. Br J Cancer; 2007 Jan 15;96(1):110-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
  • Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign breast disease (BBD) (n=263), proliferative BBD without atypia (n=128), proliferative BBD with atypia (n=11), carcinoma in situ (n=15) or invasive carcinoma (n=34) and for EGFR protein in a subset of 71 of these cases.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Neoplasm Proteins / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis / methods. Polymerase Chain Reaction / methods. RNA / genetics. Sensitivity and Specificity. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1048-50 [9870850.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Gut. 1999 Aug;45(2):246-51 [10403737.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3866-9 [10463571.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9102-10 [15489891.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2056-62 [15570308.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1265-71 [15809717.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1681-5 [16030101.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1027-33 [15920544.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1769-72 [10974624.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:443-8 [11085938.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1227-32 [11221855.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):119-30 [11438460.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3376-84 [11454885.001]
  • [Cites] JAMA. 2001 Nov 21;286(19):2441-9 [11712940.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3869-73 [11751477.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]
  • [Cites] Clin Exp Metastasis. 2002;19(4):351-8 [12090476.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4054-60 [12124341.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3105-17 [12374678.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):748-54 [12473516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):187-98 [12825853.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):854-62 [14566838.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9 [14973380.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3775-9 [15007172.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):374-7 [15047740.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):38-43 [15104281.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 15;428(2):160-4 [15246872.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5745-52 [15313915.001]
  • [Cites] J Natl Cancer Inst. 1991 May 1;83(9):648 [1859552.001]
  • [Cites] Science. 1995 Feb 10;267(5199):891-3 [7531366.001]
  • [Cites] Cytometry. 1994 Nov 1;17(3):258-65 [7851161.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Mar;101(2):109-15 [9494611.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):334-42 [9699523.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8613-6 [16204026.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7503-11 [16234517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6 [16829574.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):267-74 [10637239.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):236-40 [9988281.001]
  • (PMID = 17164758.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC2360209
  •  go-up   go-down


6. El-Attar HA, Ragab MS, Sheta MI, Ahmed AS: Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev; 2010;11(4):893-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers.
  • BACKGROUND: Hepatocyte growth factor (HGF) also known as scatter factor (SF) and its receptor c-met play important roles in mammary differentiation and have been implicated in mammary carcinogenesis.
  • OBJECTIVE: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters.
  • SUBJECTS: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas.
  • METHODS: A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed.
  • RESULTS: Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group.
  • CONCLUSION: The serum level of HGF is an independent prognostic indicator for breast cancer.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / blood. Hepatocyte Growth Factor / blood
  • [MeSH-minor] Age Factors. Egypt. Female. Fibrocystic Breast Disease / blood. Humans. Inflammation / blood. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Burden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133597.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


7. Lee JH, Kim SH, Kang BJ, Lee AW, Song BJ: Ultrasonographic features of benign adenomyoepithelioma of the breast. Korean J Radiol; 2010 Sep-Oct;11(5):522-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic features of benign adenomyoepithelioma of the breast.
  • OBJECTIVE: The purpose of this study was to evaluate the ultrasonographic features of benign adenomyoepithelioma of the breast.
  • MATERIALS AND METHODS: Between 2005 and 2009, five patients had histologically confirmed adenomyoepithelioma of the breast.
  • The ultrasonographic assessments were classified as Breast Imaging Reporting and Data System (BI-RADS) category 4A, with low suspicion of malignancy in two cases, and as category 4B, with intermediate suspicion of malignancy in three cases.
  • The pathology revealed benign adenomyoepithelioma in all patients.
  • CONCLUSION: Benign adenomyoepitheliomas appear as solid or complex echoic masses with suspicious malignant ultrasonographic features, which may be associated with adjacent ductectasia.
  • Although adenomyoepithelioma is a rare breast tumor, awareness of its sonographic features will be helpful for the differential diagnosis from other tumors.
  • [MeSH-major] Adenomyoepithelioma / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):488-90 [10834021.001]
  • [Cites] J Ultrasound Med. 2001 Sep;20(9):1021-4 [11549151.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):383-4 [12390363.001]
  • [Cites] AJR Am J Roentgenol. 2003 Mar;180(3):799-803 [12591699.001]
  • [Cites] Breast. 2004 Aug;13(4):356-8 [15325675.001]
  • [Cites] Breast Cancer. 2007;14(4):429-33 [17986811.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1232-7 [2824328.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):868-76 [1384377.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):386 [16848857.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):203-4 [17319866.001]
  • [Cites] Acta Radiol. 2007 Feb;48(1):27-9 [17325921.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • (PMID = 20808695.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2930160
  • [Keywords] NOTNLM ; Adenomyoepithelioma / Breast / Ultrasonography
  •  go-up   go-down


8. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


9. Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S: Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int J Oncol; 2005 Oct;27(4):1005-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
  • The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal breast tissue and benign and malignant breast tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2, tumor size, lymph node status and grading.
  • Seventy-three breast tissue samples were examined.
  • The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on tumor proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. Female. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142317.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Harmer V: Breast cancer. Part 1: Awareness and common benign diseases. Br J Nurs; 2008 Aug 14-Sep 10;17(15):950-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 1: Awareness and common benign diseases.
  • Breast cancer is the most common cancer for women in the United Kingdom and topic on which there is much information.
  • This article discusses the principles behind breast awareness and breast health, detailing common benign breast diseases that cause disproportionate anxiety.
  • The NHS Breast Screening Programme is celebrating 20 years of screening this year, and in all randomized controlled trials of women aged 50 and over, mortality from breast cancer is reduced in those offered screening compared with unscreened controls (although the reduction is not statistically significant in all trials).
  • Once a breast cancer is diagnosed, the different characteristics and stage of the disease can be identified through histopathology and scans.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Awareness. Diagnosis, Differential. England. Female. Humans. Mass Screening. Neoplasm Invasiveness. Referral and Consultation. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983015.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


11. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev; 2007;31(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.
  • BACKGROUND: A cohort study was conducted among post-menopausal women to determine whether genetic polymorphisms in selected obesity-related genes (PPARG, LPL, LEPR, PON1, PON2, TNF-alpha) were associated with the progression of benign breast disease (BBD) to breast cancer and whether the selected polymorphisms modified the association between body mass and breast cancer among women with BBD.
  • METHODS: Among participants in an ongoing cohort study, 994 Caucasian post-menopausal women had a breast biopsy for BBD.
  • Of these women, 61 subsequently developed breast cancer.
  • RESULTS: In this cohort, body mass index (BMI) was positively associated with the risk of developing breast cancer.
  • In contrast, polymorphisms in PON1 (Gln192Arg) and LEPR (IVS2+6920) were associated with a decreased risk of developing invasive breast cancer.
  • No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk.
  • CONCLUSIONS: The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.
  • [MeSH-major] Biomarkers, Tumor / genetics. Body Weight. Breast Diseases / genetics. Breast Neoplasms / genetics. Neoplasm Proteins / genetics. Obesity / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aryldialkylphosphatase / genetics. Cohort Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Middle Aged. PPAR gamma / genetics. Postmenopause. Receptors, Cell Surface / genetics. Receptors, Leptin. Risk Factors. Tumor Necrosis Factor-alpha / genetics

  • Genetic Alliance. consumer health - Obesity.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Body Weight.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17428620.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human; EC 3.1.8.1 / PON2 protein, human
  •  go-up   go-down


12. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • Metastatic breast cancer of skin may be seen in a number of forms.
  • It is rare to find it in association with a benign melanocytic nevus.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


14. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F: The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet; 2006 Mar;165(2):151-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
  • One hypothesis for breast cancer development suggests that breast carcinogenesis involves a progression of events leading from benign epithelium to hyperplasia (with or without atypia) to carcinoma in situ and then invasive carcinoma.
  • Benign lesions and normal adjacent cells were classified as normal.
  • The presence of MYC amplification only in invasive cells suggests that the finding of MYC amplification could reflect an advanced tumor progression.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, myc
  • [MeSH-minor] Chromosomes, Human, Pair 8. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. Paraffin Embedding

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527609.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Sabitha, Suneetha, Mohanty S, Rao P: Serum anti - TPO levels in benign and malignant breast tumors. Indian J Clin Biochem; 2009 Jul;24(3):266-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum anti - TPO levels in benign and malignant breast tumors.
  • Breast cancer is a hormone dependent neoplasm.
  • Conflicting results regarding the clinical correlation between breast cancer and thyroid diseases have been reported.
  • The objective of this study was to determine the association of anti - TPO levels in patients having complaints of a lump in breast.
  • Serum samples and Fine needle aspiration cytology (FNAC) samples were collected from 31 female patients with a lump in breast between the age group of 20-75 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1976 Jan 31;1(6004):257-9 [1082357.001]
  • [Cites] Br J Cancer. 1984 Jan;49(1):87-92 [6691901.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1232-3 [7962313.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):937-41 [8772554.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):990-4 [8772562.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2711-6 [9709936.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2783-93 [16807415.001]
  • [Cites] Indian J Clin Biochem. 2008 Jul;23(3):279-82 [23105770.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):523-8 [14870777.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):922-7 [10551319.001]
  • [Cites] J Endocrinol Invest. 2000 Jan;23(1):42-3 [10698051.001]
  • [Cites] Jpn J Cancer Res. 2001 May;92(5):483-7 [11376555.001]
  • [Cites] Internist (Berl). 2003 Apr;44(4):396-402, 404-8, 410-1 [12914397.001]
  • (PMID = 23105847.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453311
  • [Keywords] NOTNLM ; Breast cancer / FNAC / anti — TPO
  •  go-up   go-down


16. Cichon MA, Degnim AC, Visscher DW, Radisky DC: Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia; 2010 Dec;15(4):389-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.
  • Invasive breast cancer represents the endpoint of a developmental process that originates in the terminal duct lobular units and is believed to progress through stages of increasing proliferation, atypical hyperplasia, and carcinoma in situ before the cancer acquires invasive and metastatic capabilities.
  • By comparison with invasive breast cancer, which has been studied extensively, the preceding stages of benign breast disease are more poorly understood.
  • Much less is known about the molecular changes underlying benign breast disease development and progression, as well as the transition from in situ into invasive disease.
  • More challenges are posed by limitations of the models used to investigate the lesions preceding invasive breast cancer.
  • However, recent studies have identified alterations in stromal cell function that may be critical for disease progression from benign disease to invasive cancer: key functions of myoepithelial cells that maintain tissue structure are lost, while tissue fibroblasts become activated to produce proteases that degrade the extracellular matrix and trigger the invasive cellular phenotype.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):590-8 [14744773.001]
  • [Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):697-703 [9586667.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1949-58 [9815584.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):227-34 [10190302.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] J Theor Biol. 2005 Jan 21;232(2):179-89 [15530488.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):328-35 [15737842.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):446-57 [16172443.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1022-5 [16082203.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):29-33 [16397211.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Oncologist. 2006 May;11(5):435-49 [16720843.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R58 [17054791.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2671-7 [17563394.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] J Pathol. 2008 Feb;214(3):357-67 [18044827.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):370-8 [18223211.001]
  • [Cites] Cancer. 2008 May 15;112(10):2130-42 [18383519.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(2):189-98 [17624587.001]
  • [Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]
  • [Cites] Lab Invest. 2008 Jun;88(6):591-601 [18414401.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4257-64 [10628384.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]
  • [Cites] Breast Cancer Res Treat. 2000 Dec;64(3):235-40 [11200773.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):41-5 [12506168.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1601-8 [12655515.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5357-67 [18765527.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R87 [18928525.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):279-88 [19064970.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):227-32 [18936688.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):778-87 [19188147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7 [19218449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7022-7 [19369208.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R7 [19187537.001]
  • [Cites] Breast Cancer Res. 2009;11(1):101 [19291276.001]
  • [Cites] Breast Cancer Res. 2009;11 Suppl 3:S16 [20030867.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12 [20440544.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):192-208 [20452298.001]
  • [Cites] Breast Cancer Res Treat. 2010 Sep;123(2):397-404 [19949854.001]
  • [Cites] Histopathology. 2010 Aug;57(2):171-92 [20500230.001]
  • [Cites] Cancer. 2010 Nov 1;116(21):4944-53 [20645399.001]
  • [Cites] J Pathol. 2011 Jan;223(2):307-17 [21125683.001]
  • [Cites] FEBS J. 2011 Jan;278(1):16-27 [21087457.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1430-41 [15070793.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] J Natl Cancer Inst. 1973 May;50(5):1111-8 [4123242.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] JAMA. 1992 Feb 19;267(7):941-4 [1734106.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Eur J Cancer Prev. 1993 Nov;2 Suppl 3:67-76 [7507749.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):614-9 [7511693.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:112-22 [9027607.001]
  • (PMID = 21161341.001).
  • [ISSN] 1573-7039
  • [Journal-full-title] Journal of mammary gland biology and neoplasia
  • [ISO-abbreviation] J Mammary Gland Biol Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116201; United States / NCI NIH HHS / CA / CA90628-08; United States / NCI NIH HHS / CA / CA122086; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA132879; United States / NCI NIH HHS / CA / CA128660; United States / NCI NIH HHS / CA / R21 CA128660; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / R01 CA132879; United States / NCI NIH HHS / CA / R01 CA122086
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3011086
  •  go-up   go-down


17. Papachristopoulou G, Avgeris M, Scorilas A: Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost; 2009 Feb;101(2):381-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.
  • The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.
  • Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.
  • Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.
  • ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190825.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


18. Ruiz-Delgado ML, López-Ruiz JA, Eizaguirre B, Saiz A, Astigarraga E, Fernández-Temprano Z: Benign adenomyoepithelioma of the breast: imaging findings mimicking malignancy and histopathological features. Acta Radiol; 2007 Feb;48(1):27-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adenomyoepithelioma of the breast: imaging findings mimicking malignancy and histopathological features.
  • Adenomyoepithelioma of the breast is a rare neoplasm.
  • We present a case of a benign adenomyoepithelioma of the breast in an asymptomatic 60-year-old woman.
  • [MeSH-major] Adenomyoma / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mammography / methods. Myoepithelioma / diagnosis. Ultrasonography, Mammary / methods
  • [MeSH-minor] Biopsy / methods. Breast / pathology. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Middle Aged. Rare Diseases

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325921.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


19. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD: Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer; 2006 Sep 15;119(6):1403-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.
  • Matrix metalloproteinase (MMP) 2 and 9 are involved in cancer invasion and metastasis, and increased levels occur in serum and plasma of breast cancer (BC) patients.
  • In our study, we measured concentration and activity of MMP2/9 in sera of 345 donors classified as low risk (Gail score <1.7), high risk (HR) (Gail score > or =1.7), benign disease or BC.
  • Kruskal-Wallis and Mann-Whitney nonparametric tests showed that total-MMP2 concentration is higher in HR compared to control (p = 0.012), benign (p = 0.001) and cancer (p = 0.007).
  • Active MMP2 (aMMP2) concentration is higher in control than benign and cancer (p < 0.001, respectively).
  • Total and aMMP9 concentrations are higher in cancer than benign (p < 0.001, p = 0.002, respectively).
  • Total-MMP2 and total-MMP9 activities are lower in control than benign (p < 0.001, p = 0.002, respectively) and cancer (p < 0.001, respectively).
  • Total-MMP2 and MMP9 activities are also higher in cancer than benign (p = 0.004, p < 0.001) and HR (p = 0.008, p = 0.007, respectively).
  • Our study provides evidence supporting the potential role of serum MMP2/9 as biomarkers for breast disease classification.
  • [MeSH-major] Breast Diseases / enzymology. Breast Neoplasms / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Jul 1;121(1):216-8; author reply 219-23 [17315186.001]
  • (PMID = 16615109.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


21. Tse GM, Tan PH, Ma TK, Gilks CB, Poon CS, Law BK: CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol; 2005 Nov;58(11):1185-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
  • BACKGROUND/AIMS: CD44s, the standard form of CD44, has been shown to be downregulated during malignant transformation of breast cancers.
  • It has also been reported recently to be a useful marker in differentiating between benign and malignant papillary lesions of the breast, with high expression in the former.
  • CD44s expression in benign and malignant papillary lesions was evaluated.
  • METHODS: CD44s expression was assessed by immunohistochemistry in 101 benign papillomas and 59 papillary carcinomas (seven invasive papillary carcinomas, 41 papillary ductal carcinomas in situ, and 11 ductal carcinomas involving papillomas).
  • Using CD44s positive staining to differentiate between benign and malignant papillary lesions gives a sensitivity, specificity, and accuracy of 45%, 92%, and 62%, respectively.
  • CONCLUSIONS: CD44s may be useful as an adjunct in the evaluation of morphologically problematic cases of papillary lesion of the breast.
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1665-70 [15274338.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):211-31 [15339042.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):23-31 [15385106.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):276-89 [2450059.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Cancer Cells. 1991 Sep;3(9):347-50 [1721518.001]
  • [Cites] J Cell Biol. 1992 Aug;118(4):971-7 [1380003.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Curr Top Microbiol Immunol. 1993;184:47-63 [7508842.001]
  • [Cites] Bioessays. 1995 Jan;17(1):17-24 [7535522.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5424-33 [7585612.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(3):307-313 [8573713.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):125-35 [8781700.001]
  • [Cites] Clin Exp Metastasis. 1996 Oct;14(5):434-9 [8871537.001]
  • [Cites] Histopathology. 1998 Aug;33(2):107-16 [9762542.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):45-50 [10071234.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):23-9 [11245336.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2539-46 [11745187.001]
  • [Cites] J Pathol. 2001 Nov;195(4):415-21 [11745672.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):34-9 [11893033.001]
  • [Cites] Histopathology. 2003 Jun;42(6):546-54 [12786890.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Pol J Pathol. 2003;54(4):243-7 [14998292.001]
  • [Cites] Genomics. 1995 Nov 1;30(1):115-7 [8595891.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):513-8 [8621236.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):259-61 [8654608.001]
  • (PMID = 16254109.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44S antigen
  • [Other-IDs] NLM/ PMC1770758
  •  go-up   go-down


22. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


24. Wishart GC, Campisi M, Boswell M, Chapman D, Shackleton V, Iddles S, Hallett A, Britton PD: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol; 2010 Jun;36(6):535-40
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy.
  • BACKGROUND: Mammography has a lower sensitivity for breast cancer detection in younger women and those with dense breasts.
  • Recent improvements in digital infrared breast imaging suggest there may be a role for this technology and we have studied its performance in 100 women prior to breast needle core biopsy (CB).
  • METHODS: All patients were imaged using a digital infrared breast (DIB) scan (Sentinel BreastScan) prior to breast biopsy.
  • RESULTS: Of 106 biopsies performed in 100 women, 65 were malignant and 41 were benign.
  • CONCLUSION: DIB using NoTouch is an effective adjunctive test for breast cancer detection in women under 70 and appears to be particularly effective in women under 50 where maximal sensitivity (78%) and specificity (75%) were observed.
  • [MeSH-major] Breast Neoplasms / pathology. Thermography / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Humans. Infrared Rays. Middle Aged. Neoplasm Staging. Neural Networks (Computer). Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2010 Sep;7(9):483 [20824903.001]
  • (PMID = 20452740.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • The latter is a benign proliferative lesion of the breast that exhibits an increase in the size of the TDLUs and characterized by retained two-cell lining, and myoepithelial (ME) and stromal hyperplasia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Al-Khawari H, Kovacs A, Athyal R, Al-Manfouhi H, Fayaz MS, Madda JP: Breast magnetic resonance imaging: initial experience in Kuwait. Med Princ Pract; 2009;18(2):143-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast magnetic resonance imaging: initial experience in Kuwait.
  • OBJECTIVE: To report our initial experience of breast magnetic resonance imaging (MRI) in Kuwait in order to identify and characterize breast lesions.
  • SUBJECTS AND METHODS: In 58 patients ranging in age from 25 to 64 years, breast MRI was performed as a problem-solving tool (29); for suspicious local relapse of the treated breast (6); to search for a primary breast cancer in patients with metastatic axillary lymph nodes (5); for local staging of breast cancer (5); breast implants (6); screening in high-risk patients (3), and differentiation between inflammation and inflammatory carcinoma (4).
  • RESULTS: Seventy breast lesions (25 malignant, 38 benign and 7 lesions detected by MRI only) were identified in the 58 patients.
  • The sensitivity, specificity, and positive and negative predictive values of MRI in diagnosing malignant breast lesions were 96, 67, 71 and 95%, respectively, while the accuracy was 80%.
  • [MeSH-major] Breast. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Kuwait. Magnetic Resonance Imaging. Mass Screening / methods. Middle Aged. Neoplasm Staging / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19204434.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • We report cytological and histological features of tubular adenoma in a 24 year old female with brief review of literature.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


28. Fon LJ, Lioe TF, Mulligan KA, Johnston PG, McCormick D, Spence RA: Prognostic significance of glycoprotein pMQ1 in breast cancer. Br J Surg; 2006 Mar;93(3):309-14
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of glycoprotein pMQ1 in breast cancer.
  • Cerebral metastases from breast cancer have also been found to contain pMQ1-positive cells.
  • This study aimed to determine the role of pMQ1 in primary breast cancer.
  • METHODS: Breast cancer specimens were analysed for pMQ1 by immunohistochemistry.
  • RESULTS: pMQ1 was expressed in most of the breast cancer specimens.
  • The surrounding normal tissue margins and benign breast tissues always lacked pMQ1 expression.
  • [MeSH-major] Breast Neoplasms / chemistry. Glycoproteins / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Breast / chemistry. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 16392102.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 0 / pMQ1 glycoprotein, human
  •  go-up   go-down


29. Hoehne FM, Taylor E: Trends in breast cancer at a county hospital. Am Surg; 2005 Feb;71(2):159-63
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in breast cancer at a county hospital.
  • Breast cancer mortality has changed dramatically with improvements in screening techniques.
  • We report our experience in breast biopsies at a county teaching hospital with a traditionally younger patient population.
  • A total of 550 breast biopsies were conducted between 1995 and 2000.
  • Data regarding age, method of breast biopsy, and pathology was reviewed.
  • One hundred twenty of 550 patients (21.8%) had breast carcinoma detected on breast biopsies with the predominant histologic subtype being invasive ductal carcinoma.
  • The mean age of patients with carcinoma was 52.8 years, whereas that of patients with benign breast disease was 43.6 years (P < 0.05).
  • Forty-three per cent of all breast cancers occurred in women under the age of 50 years.
  • During the study period, there was neither an increase in the number of breast biopsies performed per year nor a decrease in the average age of women with breast cancer.
  • However, observing a significant percentage of breast cancer patients under 50 years old, our data suggest the importance of strict adherence to current screening recommendations including self-breast examination and yearly mammography.
  • [MeSH-major] Breast Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy / statistics & numerical data. Breast / pathology. Breast Self-Examination / statistics & numerical data. California / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / epidemiology. Female. Hospitals, County / statistics & numerical data. Hospitals, Teaching / statistics & numerical data. Humans. Mammography / statistics & numerical data. Mass Screening / statistics & numerical data. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16022017.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


31. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas.
  • This study demonstrates the usefulness of NGFR as a new adjunct marker to identify myoepithelial cells in preinvasive lesions and myoepithelial differentiation in breast carcinomas.
  • Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Nerve Tissue Proteins / analysis. Receptors, Growth Factor / analysis
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


32. Tsui PH, Yeh CK, Liao YY, Chang CC, Kuo WH, Chang KJ, Chen CN: Ultrasonic Nakagami imaging: a strategy to visualize the scatterer properties of benign and malignant breast tumors. Ultrasound Med Biol; 2010 Feb;36(2):209-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonic Nakagami imaging: a strategy to visualize the scatterer properties of benign and malignant breast tumors.
  • Previous studies have demonstrated the usefulness of the Nakagami parameter in characterizing breast tumors by ultrasound.
  • However, physicians or radiologists may need imaging tools in a clinical setting to visually identify the properties of breast tumors.
  • This study proposed the ultrasonic Nakagami image to visualize the scatterer properties of breast tumors and then explored its clinical performance in classifying benign and malignant tumors.
  • Raw data of ultrasonic backscattered signals were collected from 100 patients (50 benign and 50 malignant cases) using a commercial ultrasound scanner with a 7.5 MHz linear array transducer.
  • The backscattered signals were used to form the B-scan and the Nakagami images of breast tumors.
  • For each tumor, the average Nakagami parameter was calculated from the pixel values in the region-of-interest in the Nakagami image.
  • The results showed that the Nakagami image shadings in benign tumors were different from those in malignant cases.
  • The average Nakagami parameters for benign and malignant tumors were 0.69 +/- 0.12 and 0.55 +/- 0.12, respectively.
  • This means that the backscattered signals received from malignant tumors tend to be more pre-Rayleigh distributed than those from benign tumors, corresponding to a more complex scatterer arrangement or composition.
  • The results showed that the Nakagami image is useful to distinguishing between benign and malignant breast tumors.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography. Neoplasms / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Scattering, Radiation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20018436.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Chandru H, Sharada AC, Manjunath S: [Expression of matrix metalloproteinase (MMP-2) and extracellular matrix metalloproteinases inducer (EMMPRIN) in benign and advanced breast cancer tissue samples]. Biomed Khim; 2007 Jul-Aug;53(4):461-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of matrix metalloproteinase (MMP-2) and extracellular matrix metalloproteinases inducer (EMMPRIN) in benign and advanced breast cancer tissue samples].
  • Tumor cell derived matrix metalloproteinases are a family of enzymes associated with the tumor invasion and metastasis.
  • In the present study the role of MMP-2 and EMMPRIN in the progression of breast cancer has been investigated.
  • Gelatinase-A and EMMPRIN were analyzed in benign and stage II and stage III breast cancer tissue samples by gelatin zymography assay, immunoprecipation analysis and Western blot analysis with a monoclonal primary antibody specific for EMMPRIN.
  • Our results showed overexpression of EMMPRIN in advanced stages of breast cancer tissues compared with benign tumor tissue samples.
  • The expression of MMP-2, the active and latent forms of the enzyme increased with tumor progression from Stage II to Stage III of breast cancer and it was not expressed in benign tissues.
  • The expression MMP-2 correlates with tumor progression.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Mammary Glands, Human / metabolism. Matrix Metalloproteinase 2 / biosynthesis
  • [MeSH-minor] Female. Humans. Immunoprecipitation. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035727.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


34. Nadelman CM, Leslie KO, Fishbein MC: "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases. Arch Pathol Lab Med; 2006 Sep;130(9):1349-53
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases.
  • Adenomyoepitheliomas of the breast are rare tumors composed of a proliferation of 2 cell populations.
  • For the most part, they are considered to be benign, but they locally recur.
  • Those neoplasms that metastasize are deemed to have come from a histologically malignant primary tumor.
  • Herein, we describe 2 cases of metastases of histologically "benign" adenomyoepitheliomas of the breast to the lung.
  • Establishing the diagnosis, determining optimal therapy, and predicting outcome are problematic because of the rarity of this entity.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948523.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. De Vries J, Van der Steeg AF, Roukema JA: Determinants of fatigue 6 and 12 months after surgery in women with early-stage breast cancer: a comparison with women with benign breast problems. J Psychosom Res; 2009 Jun;66(6):495-502
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of fatigue 6 and 12 months after surgery in women with early-stage breast cancer: a comparison with women with benign breast problems.
  • OBJECTIVE: The objective of this study was to examine the predictors of fatigue 6 and 12 months after surgical treatment in women with early-stage breast cancer (BC group) and in women with benign breast problems (BBP group) in a prospective follow-up study.
  • METHODS: Women entered the study prior to diagnosis and completed questionnaires on personality factors, psychological factors, and social support.
  • Fatigue was assessed 6 and 12 months after diagnosis (BBP group) or surgical treatment (BC group).
  • CONCLUSION: Many patients who are already fatigued before diagnosis remain tired regardless of diagnosis.
  • [MeSH-major] Breast Diseases / epidemiology. Breast Neoplasms. Fatigue / diagnosis. Fatigue / epidemiology. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Anxiety Disorders / diagnosis. Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Cognition. Demography. Female. Humans. Middle Aged. Personality Disorders / diagnosis. Personality Disorders / epidemiology. Postoperative Period. Predictive Value of Tests. Prospective Studies. Severity of Illness Index. Social Support. Surveys and Questionnaires. Time Factors


36. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology
  • [MeSH-minor] Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Intercellular Adhesion Molecule-1 / immunology. Intercellular Adhesion Molecule-1 / metabolism. Lymphocytes / immunology. Lymphocytes / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


37. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer; 2010;10:483
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.
  • BACKGROUND: Breast cancer is a heterogeneous disease associated with different patient prognosis and responses to therapy.
  • We aimed to study the expression of these three proteins by immunohistochemistry in a series of breast lesions.
  • METHODS: We have used a cohort comprising normal breast, benign mammary lesions, carcinomas in situ and invasive carcinomas and assessed the expression of the VDR, CYP27B1 and CYP24A1 by immunohistochemistry.
  • RESULTS: The results that we have obtained show that all proteins are expressed in the various breast tissues, although at different amounts.
  • The VDR was frequently expressed in benign lesions (93.5%) and its levels of expression were diminished in invasive tumours (56.2%).
  • Additionally, the VDR was strongly associated with the oestrogen receptor positivity in breast carcinomas.
  • CYP27B1 expression is slightly lower in invasive carcinomas (44.6%) than in benign lesions (55.8%).
  • In contrast, CYP24A1 expression was augmented in carcinomas (56.0% in in situ and 53.7% in invasive carcinomas) when compared with that in benign lesions (19.0%).
  • CONCLUSIONS: From this study, we conclude that there is a deregulation of the Vitamin D signalling and metabolic pathways in breast cancer, favouring tumour progression.
  • [MeSH-major] 25-Hydroxyvitamin D3 1-alpha-Hydroxylase / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Receptors, Calcitriol / metabolism. Steroid Hydroxylases / metabolism. Vitamin D / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cohort Studies. Disease Progression. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Metabolic Networks and Pathways. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Vitamin D3 24-Hydroxylase

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Metastasis. 1994 May;12(3):195-202 [8194194.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):239-44 [1846309.001]
  • [Cites] J Histochem Cytochem. 1998 Nov;46(11):1335-7 [9774633.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1721S-4S [15585794.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3579-86 [15867263.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28 [15951480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2370-6 [16214919.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):688-94 [16012853.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):153-64 [16111884.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R980-6 [16280049.001]
  • [Cites] Science. 2006 Apr 14;312(5771):233-6 [16614213.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92 [16828283.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Virchows Arch. 2007 Jan;450(1):73-80 [17123107.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):684-700 [17721433.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1257-64 [17875655.001]
  • [Cites] Proc Nutr Soc. 2008 May;67(2):115-27 [18412986.001]
  • [Cites] J Cell Biochem. 2008 Nov 1;105(4):980-8 [18767073.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):155-7 [19331145.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1328-33 [19437538.001]
  • [Cites] Mol Pharmacol. 2009 Oct;76(4):702-9 [19570947.001]
  • [Cites] J Cell Biochem. 1999 Dec 15;75(4):640-51 [10572247.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):144-6 [10835626.001]
  • [Cites] Circ Res. 2000 Aug 4;87(3):214-20 [10926872.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3371-9 [10955825.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Histochem J. 2002 Jan-Feb;34(1-2):35-40 [12365798.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):67-80 [12644300.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Cancer Res. 1987 Dec 15;47(24 Pt 1):6793-9 [2824042.001]
  • [Cites] Science. 1988 May 13;240(4854):889-95 [3283939.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):607-13 [2842365.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):233-9 [2458030.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • (PMID = 20831823.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D; EC 1.14.- / 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / CYP24A1 protein, human; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase
  • [Other-IDs] NLM/ PMC2945944
  •  go-up   go-down


38. Yang J, Hu A, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T: NOEY2 mutations in primary breast cancers and breast hyperplasia. Breast; 2009 Jun;18(3):197-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOEY2 mutations in primary breast cancers and breast hyperplasia.
  • PURPOSE: The NOEY2 gene mutations and protein expression in human breast cancers, adjacent breast tissues and breast benign lesions were analysed to explore the potential correlation between the mutation spectrum and breast cancer development and progression.
  • EXPERIMENTAL DESIGN: The promoter, exon and intron regions of NOEY2 gene were amplified by polymerase chain reaction (PCR) with DNA extracted from 50 human breast cancer and corresponding adjacent breast tissues as well as 50 breast benign lesions, respectively.
  • RESULTS: Twenty-one of 50 (42%) breast cancer mutations were identified in promoter (11 cases) and exon 2 (seven cases on untranslation region and three on coding region) and 17 of 50 (34%) adjacent breast tissues (all were atypical hyperplasia lesions) occurred mutations, including six promoter mutations and 11 exon 2 changes (10 cases on untranslation region and one on coding region).
  • Interestingly, the mutations were identified in both breast cancers and the corresponding adjacent breast tissues collected from the same patient in seven of them.
  • No mutation was identified in all benign breast tissues.
  • Immunohistochemical analysis showed that two of 17 mutational adjacent breast tissue samples were NOEY2 immunoreaction negative, and in all 21 mutations of breast cancers five cases were of loss of NOEY2 expression.
  • CONCLUSIONS: The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.
  • The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. rho GTP-Binding Proteins / metabolism
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis / methods. Female. Gene Expression Regulation, Neoplastic. Humans. Hyperplasia / genetics. Hyperplasia / pathology. Immunohistochemistry. Middle Aged. Mutation. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482475.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DIRAS3 protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


39. Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA: Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med; 2010 Oct 25;207(11):2421-37
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion.
  • In this study, we report that FLNa suppresses invasion of breast cancer cells and regulates focal adhesion (FA) turnover.
  • Two large progression tissue microarrays from breast cancer patients revealed a significant decrease of FLNa levels in tissues from invasive breast cancer compared with benign disease and in lymph node-positive compared with lymph node-negative breast cancer.
  • In breast cancer cells and orthotopic mouse breast cancer models, down-regulation of FLNa stimulated cancer cell migration, invasion, and metastasis formation.
  • These results document a regulation of FA dynamics by FLNa in breast cancer cells.


40. Wauters CA, Sanders-Eras MC, de Kievit-van der Heijden IM, Wesseling P, Venderink DJ, van Dijk Azn R, van den Wildenberg F, Kooistra BW, Strobbe LJ: Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions. Eur J Surg Oncol; 2010 Oct;36(10):957-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions.
  • AIM: A quick and reliable preliminary diagnosis is essential in the management of a same-day breast clinic.
  • METHODS: From April 2008 to April 2009, biopsies were taken from lesions in the breast.
  • CWC was obtained from core needle biopsy (CNB) with a modified technique and classified into the categories: malignant, suspicious for malignancy, atypical, benign and inadequate.
  • RESULTS: CWC was obtained from 226 breast lesions.
  • In 167 of these cases subsequent resection of the lesion was performed revealing 149 carcinomas and 18 benign lesions.
  • Of the 149 malignant cases, 136 were considered as either malignant or suspicious for malignancy by CWC, 7 as atypical, 4 as benign and 2 as inadequate.
  • None of the 18 benign lesions were classified as suspicious or malignant on CWC.
  • CONCLUSIONS: In the vast majority of patients the modified CWC technique can provide a quick and reliable diagnosis of malignant breast lesions.
  • Furthermore, combining CWC with CNB histology can improve adequate, preoperative recognition of the malignant character of breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Ambulatory Care / methods. Breast Diseases / diagnosis. Breast Diseases / pathology. Breast Diseases / surgery. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Netherlands. Preoperative Care / methods. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708371.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Zhu Q, Hegde PU, Ricci A Jr, Kane M, Cronin EB, Ardeshirpour Y, Xu C, Aguirre A, Kurtzman SH, Deckers PJ, Tannenbaum SH: Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology; 2010 Aug;256(2):367-78
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis.
  • PURPOSE: To investigate the potential role of optical tomography in the near-infrared (NIR) spectrum with ultrasonographic (US) localization as a means of differentiating early-stage cancers from benign lesions of the breast.
  • From this measurement, tumor angiogenesis was assessed on the basis of calculated total hemoglobin concentration (tHb) and was correlated with core biopsy results.
  • RESULTS: There were two in situ carcinomas (Tis), 35 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.
  • The mean maximum and mean average tHb of the benign group were 55.1 micromol/L +/- 22.7 and 39.1 micromol/L +/- 14.9, respectively.
  • Both mean maximum and mean average tHb levels were significantly higher in the malignant groups than they were in the benign group (P < .001).
  • CONCLUSION: The angiogenesis (tHb) contrast imaged by using the NIR technique with US holds promise as an adjunct to mammography and US for distinguishing early-stage invasive breast cancers from benign lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2004 Jan;230(1):42-8 [14695385.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):301-8 [8611096.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Radiology. 2004 Dec;233(3):857-67 [15567802.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):72-9 [15797295.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):328-35 [15905718.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):440-8 [16683089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):365-80 [16866567.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5474-9 [17875777.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):539-44 [18267357.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):859-66 [18572121.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044002 [19021330.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1363-80 [19197974.001]
  • [Cites] Radiology. 2009 Sep;252(3):665-72 [19567644.001]
  • [Cites] J Biomed Opt. 2009 Jul-Aug;14(4):044005 [19725717.001]
  • [Cites] Clin Radiol. 2000 Jan;55(1):40-4 [10650109.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • (PMID = 20571122.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002136
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2909434
  •  go-up   go-down


42. Rinaldi P, Giuliani M, Belli P, Costantini M, Romani M, Distefano D, Bufi E, Mulè A, Magno S, Masetti R, Bonomo L: DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients. Eur J Radiol; 2010 Aug;75(2):e114-23
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWI in breast MRI: role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients.
  • INTRODUCTION: Purpose of our study is to evaluate the role of the apparent diffusion coefficient (ADC) in the diagnosis of recurrent tumor on the scar in patients operated for breast cancer.
  • Assess, therefore, the weight of diagnostic diffusion echo-planar sequence, in association with the morphological and dynamic sequences in the diagnosis of tumor recurrence versus surgical scar.
  • MATERIALS AND METHODS: From September 2007 to March 2009, 72 patients operated for breast cancer with suspected recurrence on the scar were consecutively subjected to magnetic resonance imaging (MRI), including use of a diffusion sequence.
  • RESULTS: 26 cases were positive/doubtful at MRI and then subjected to histological typing: of these recurrences were 20 and benign were 6.
  • CONCLUSIONS: ADC value can be a specific parameter in differential diagnosis between recurrence and scar.
  • The diffusion sequence, in association with the morphological and dynamic sequences, can be considered a promising tool for the surgical indication in suspected recurrence of breast cancer.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Cicatrix / diagnosis. Diffusion Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20172677.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


43. Maxwell AJ: Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience. Clin Radiol; 2009 Aug;64(8):801-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided vacuum-assisted excision of breast papillomas: review of 6-years experience.
  • AIM: To review the outcome of vacuum-assisted removal of breast papillomas performed in the Bolton Breast Unit.
  • MATERIALS AND METHODS: Twenty-six benign breast papillomas were excised using an ultrasound-guided, vacuum-assisted technique under local anaesthetic over a 6-year period.
  • Subsequent breast imaging (mostly routine screening mammography) was reviewed and evidence of recurrence recorded.
  • All three recurrent lesions were surgically excised and confirmed to be benign papillomas.
  • [MeSH-major] Breast Neoplasms / surgery. Papilloma, Intraductal / surgery. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Biopsy / methods. Breast / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / ultrasonography. Treatment Outcome. Ultrasonography, Mammary. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589419.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z: Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res; 2009 Jun;7(6):832-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.
  • But its function in breast cancer was not yet clarified completely.
  • We detected RKIP expression in clinical samples of primary breast cancer, breast cancer metastases, and in different breast cancer cells.
  • Compared with the normal breast epithelia, benign breast epithelia, or in situ ductal carcinoma, the expression level of RKIP is decreased in invasive carcinoma and significantly reduced or lost in the metastasis lymph node matched to the invasive carcinoma.
  • To explore the potential role of RKIP in breast cancer metastasis, we studied the effect of RKIP on the malignant phenotypes of the breast cancer cells with ectopically overexpression or knockdown of RKIP.
  • Consistent with these results, in the orthotopic murine models, we observed that overexpression of RKIP in breast cancer cells impaired invasiveness and metastasis, whereas down-regulation of RKIP expression promoted invasiveness and metastasis.
  • These results indicate that RKIP is a metastasis suppressor gene of human breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / biosynthesis
  • [MeSH-minor] Analysis of Variance. Animals. Cell Adhesion / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Statistics, Nonparametric. Tissue Distribution


45. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ: A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of relative telomere length and postmenopausal breast cancer risk.
  • During breast cancer progression, a substantial increase in chromosomal aberrations is observed in the transition from ductal hyperplasia to carcinoma in situ.
  • Consequently, telomere dysfunction, which leads to genomic instability, is hypothesized to play a causal role in the progression of breast cancer.
  • However, the few epidemiologic studies that have assessed the relationship between telomere length and breast cancer risk have been inconsistent.
  • We used quantitative real-time PCR to measure relative telomere length in genomic DNA extracted from peripheral blood leukocytes and examined its association with postmenopausal breast cancer risk in 1,122 invasive breast cancer cases and 1,147 matched controls free of diagnosed cancer nested within the prospective Nurses' Health Study.
  • Our data show that relative telomere length was not associated with a significant elevation in postmenopausal breast cancer risk [below versus above median; odds ratio, 1.23; 95% confidence interval, 0.94-1.60; P(trend) = 0.20].
  • Other established breast cancer risk factors such as family history of breast cancer and history of benign breast disease were not associated with relative telomere length in separate linear regression models each adjusted for age and disease status (P > or = 0.07).
  • Our results provide little support for an important role of telomere length, as measured in peripheral blood leukocytes, as a biomarker of breast cancer risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 May 15;68(10):3618-23 [18483243.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1696-700 [18000505.001]
  • [Cites] Mech Ageing Dev. 2000 Nov 15;119(3):89-99 [11080530.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e47 [12000852.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2900-6 [3986816.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]
  • [Cites] Curr Opin Oncol. 1996 Jan;8(1):66-71 [8868103.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1823-30 [16567770.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:531-57 [16824017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] Aging Cell. 2007 Dec;6(6):769-74 [17925004.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5917-21 [10606235.001]
  • (PMID = 19293310.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082838; United States / NCI NIH HHS / CA / CA065725; United States / NCI NIH HHS / CA / R01 CA049449-19; United States / NCI NIH HHS / CA / R01 CA065725-05; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / T32 CA009001-33; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA132190-02; United States / NCI NIH HHS / CA / CA49449; United States / NCI NIH HHS / CA / CA009001-33; United States / NCI NIH HHS / CA / R01 CA065725; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R03 CA132190-02; United States / NCI NIH HHS / CA / T32 CA09001; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / CA132190; United States / NCI NIH HHS / CA / R03 CA132190; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / CA065725-05; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / U01 CA049449; United States / NCI NIH HHS / CA / R01 CA082838-09
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS102391; NLM/ PMC2732000
  •  go-up   go-down


46. Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, Boguniewicz A, Ross JS: Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer; 2009 Jun 15;124(12):2829-36
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.
  • WWP1, a HECT type E3 ubiquitin ligase frequently amplified and overexpressed in breast cancer, has the potential to become a useful clinical biomarker and therapeutic target in breast cancer.
  • The normal breast epithelium and adjacent benign epithelium are essentially negative for WWP1.
  • The positive correlations between WWP1 and ER/IGF-1R were also observed in a panel of 12 breast cancer cell lines by Western blot.
  • Interestingly, the ER levels are decreased when WWP1 is silenced in ER positive MCF7 and T47D breast cancer cell lines.
  • These findings suggest that WWP1 may play an important role in ER positive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / metabolism. Estrogen Receptor alpha / metabolism. Receptor, IGF Type 1 / metabolism. Ubiquitin-Protein Ligases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / pharmacology. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Proliferation / drug effects. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. RNA, Small Interfering / pharmacology. Tamoxifen / pharmacology. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • (PMID = 19267401.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / RNA, Small Interfering; 0 / estrogen receptor alpha, human; 094ZI81Y45 / Tamoxifen; EC 2.7.10.1 / Receptor, IGF Type 1; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / WWP1 protein, human
  •  go-up   go-down


47. Goicoechea SM, Bednarski B, García-Mata R, Prentice-Dunn H, Kim HJ, Otey CA: Palladin contributes to invasive motility in human breast cancer cells. Oncogene; 2009 Jan 29;28(4):587-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palladin contributes to invasive motility in human breast cancer cells.
  • In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in tumors compared with benign breast tissue, and also expressed significantly higher in four invasive breast cancer cell lines when compared with four non-invasive cell lines.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2006;38(11):1875-92 [16790362.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):974-82 [16430883.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4402-9 [16807943.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):568-79 [16897755.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2387-96 [16794588.001]
  • [Cites] Proteomics. 2006 Dec;6(23):6300-16 [17133371.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e516 [17194196.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):296-305 [17211471.001]
  • [Cites] Breast Cancer Res Treat. 1999 Dec;58(3):193-204 [10718481.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):643-56 [10931874.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5168-78 [11431356.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2721-9 [11553711.001]
  • [Cites] Mol Biol Cell. 2001 Oct;12(10):3060-73 [11598191.001]
  • [Cites] Exp Cell Res. 2002 Oct 15;280(1):64-74 [12372340.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2482-91 [12808045.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):376-85 [12837608.001]
  • [Cites] Trends Cell Biol. 2007 Mar;17(3):107-17 [17275303.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2657-65 [17363586.001]
  • [Cites] J Cell Biochem. 2007 Apr 1;100(5):1288-300 [17115415.001]
  • [Cites] Circ Res. 2007 Mar 30;100(6):817-25 [17322171.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1773(5):642-52 [16926057.001]
  • [Cites] Immunity. 2007 Jun;26(6):784-97 [17570692.001]
  • [Cites] Exp Cell Res. 2007 Jul 15;313(12):2575-85 [17537434.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):205-18 [17537571.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2962-73 [17885682.001]
  • [Cites] BMC Cancer. 2007;7:198 [17956604.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6222-31 [18180288.001]
  • [Cites] Mol Cell Neurosci. 2003 Aug;23(4):661-8 [12932445.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Feb;57(2):84-95 [14691948.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 May;58(1):17-29 [14983521.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1600-8 [14767055.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):421-32 [15138294.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):30-4 [15147863.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57 [15366708.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5702-10 [7923219.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1383-93 [9508771.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):501-12 [9872598.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4440-9 [10442635.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):155-65 [15710328.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):208-21 [15784178.001]
  • [Cites] Mol Cell Neurosci. 2005 Aug;29(4):507-15 [15950489.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]
  • [Cites] Int Rev Cytol. 2005;246:31-58 [16164966.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):88-98 [16125169.001]
  • [Cites] FEBS J. 2006 Jan;273(1):26-33 [16367745.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):995-1004 [16492705.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):151-7 [16546557.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] J Cell Sci. 2006 Aug 15;119(Pt 16):3316-24 [16868024.001]
  • (PMID = 18978809.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009688; United States / NIGMS NIH HHS / GM / GM61743; United States / NIGMS NIH HHS / GM / R01 GM061743; United States / NIGMS NIH HHS / GM / GM061743-04; United States / NIGMS NIH HHS / GM / R01 GM061743-04; United States / NCI NIH HHS / CA / CA098240; United States / NCI NIH HHS / CA / CA09688; United States / NCI NIH HHS / CA / K08 CA098240
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / palladin protein, human; 0 / palladin protein, mouse
  • [Other-IDs] NLM/ NIHMS72118; NLM/ PMC2633435
  •  go-up   go-down


48. Al-Harris ES, Al-Janabi AA, Al-Toriahi KM, Yasseen AA: Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J; 2008 Aug;29(8):1099-104
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
  • OBJECTIVE: To assess the significance of vascular endothelial growth factor (VEGF) protein over expression in human breast cancer, and its possible correlation with cell proliferation marker (Ki-67), grade and stage of breast cancer.
  • A retrospective study was employed on paraffin-embedded blocks from 52 female patients with breast cancer.
  • A group of 21 patients with benign breast lesions was included for comparison and 14 cases of normal breast tissue as a control group.
  • Vascular endothelial growth factor immunoexpression was considered as positive in 61.5% of malignant and in 19% of benign breast lesions.
  • No over expression sign has been noticed in normal breast tissue (p<0.005).
  • No significant difference in VEGF over expression among different histological types of breast cancer (p>0.05).
  • Vascular endothelial growth factor immunostaining was positively correlated with Ki-67, grade, stage, lymph node metastasis, and recurrence of breast cancer (p<0.05).
  • CONCLUSION: Vascular endothelial growth factor Vascular endothelial growth factor plays an important role in pathogenesis of breast cancer evolution, and supports the evidence of its role in angiogenesis and cell survival.
  • [MeSH-major] Breast Neoplasms / pathology. Ki-67 Antigen / analysis. Neoplasm Staging. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690299.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


49. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • MATERIALS AND METHODS: This case-control study was carried out on 52 female patients in the age-group of 18-70 years.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


50. Martínez-Galán J, Torres B, Del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, Núñez MI, Luna Jde D, Oliver FJ, Ruiz de Almodóvar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther; 2008 Jun;7(6):958-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
  • The aim of the present study was to investigate the association between gene hypermethylation and main clinicopathological features of breast cancer, including diagnosis and treatment response.
  • A sensitive SYBR green methylation-specific PCR technique was used to analyze the utility of circulating DNA with CpG island hypermethylation of ESR1, APC, RARB, 14-3-3-sigma and E-cad gene promoter regions as breast cancer biomarkers.
  • Analyses were conducted of preoperative sera from 106 women with breast cancer, 34 with benign breast disease and 74 with no evidence of breast disease and of post-treatment sera from 60 of the breast cancer patients.
  • Mean serum values of methylated ESR1 and 14-3-3-sigma gene promoters significantly differed between breast cancer patients and healthy controls (p = 0.0112 for ESR1 and p = 0.0047 for 14-3-3-sigma).
  • When their results were combined, it was found that hypermethylation of these two genes differentiated between breast cancer patients and healthy controls (p < 0.0001) with a sensitivity of 81% (95% confidence interval: 72-88%) and specificity of 88% (95% CI: 78-94%).
  • Presence of methylated ESR1 in serum of breast cancer patients was associated with the ER negative phenotype (p = 0.0179).
  • Serum hypermethylation at ESR1 and 14-3-3-sigma loci was observed in cancer patients, in situ carcinoma and benign breast disease.
  • Preliminary clinical applications of this approach have revealed several shortcomings, including a frequent presence of methylated 14-3-3-sigma in sera from women with breast benign disease.
  • These findings cast some doubts on the utility for early cancer diagnosis of highly sensitive techniques to identify hypermethylation of specific gene promoters in DNA extracted from serum.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Case-Control Studies. DNA Methylation. DNA, Neoplasm / metabolism. Disease Progression. Exoribonucleases. Female. Humans. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379196.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


51. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA: IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J; 2008 May-Jun;14(3):261-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.
  • Overexpression of IGFBP2 and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of breast cancer have not been investigated in detail.
  • To determine their roles, we examined IGFBP2 and IGFBP5 expression levels in 164 T1 breast carcinomas using tissue microarrays and immunohistochemistry.
  • No or very low expression of IGFBP2 and IGFBP5 was detected in normal breast epithelium or benign breast tissue with fibrocystic change.
  • Moderate to strong cytoplasmic staining for IGFBP2 and IGFBP5 was detected in 49.1% and 50.3% of T1 invasive breast carcinomas, respectively.
  • IGFBP2 and IGFBP5 expression correlated with the expression status of progesterone receptor and HER-2/neu in the overall T1 carcinoma group, but no association was found with tumor size or the expression status of estrogen receptor.
  • Our data suggest that IGFBP2 and IGFBP5 play a role in the development of metastasis and may serve as useful markers to predict lymph node metastasis in patients with small (T1) invasive breast carcinomas.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Insulin-Like Growth Factor Binding Protein 2 / biosynthesis. Insulin-Like Growth Factor Binding Protein 5 / biosynthesis
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373644.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


52. Michalopoulos NV, Zagouri F, Sergentanis TN, Pararas N, Koulocheri D, Nonni A, Filippakis GM, Chatzipantelis P, Bramis J, Zografos GC: Needle tract seeding after vacuum-assisted breast biopsy. Acta Radiol; 2008 Apr;49(3):267-70
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle tract seeding after vacuum-assisted breast biopsy.
  • PURPOSE: To assess cell seeding along the needle tract of vacuum-assisted breast biopsy (VABB).
  • In 2/31 (6.5%) cases (95% CI 0.8-21.4%), benign epithelial cell displacement was observed, and the duration of VABB was significantly longer in these two cases (52.5+/-3.5 min vs. 42.0+/-4.4 min for cases without benign cell displacement; P = 0.018, Mann-Whitney-Wilcoxon test for independent samples).
  • Benign cell displacement was associated with longer VABB duration.
  • The phenomenon of tumor cell dissemination along the needle tract is of questionable clinical significance when the treatment guidelines are followed.
  • [MeSH-major] Biopsy, Needle / adverse effects. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Neoplasm Seeding
  • [MeSH-minor] Female. Guideline Adherence. Humans. Mastectomy. Time Factors. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365811.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


53. Cyran CC, Fu Y, Raatschen HJ, Rogut V, Chaopathomkul B, Shames DM, Wendland MF, Yeh BM, Brasch RC: New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging; 2008 Mar;27(3):581-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
  • MATERIALS AND METHODS: Thirty-two athymic rats with human breast cancer xenografts (MDA-MB-435) were imaged by dynamic MRI following enhancement with one of three new (Gd-DOTA)-conjugated PEG-core dendrimer contrast agents (effective molecular weights 161 to 323 kDa).
  • 100 cm(3)) and tumor fractional plasma volumes (%) based on a two-compartment kinetic model were performed for skeletal muscle and tumors.
  • RESULTS: The largest PEG-core contrast agent, PEG(20,000)-Gen4-(Gd-DOTA), leaked in breast tumors (K(PS) = 50 +/- 23 microL/min .
  • CONCLUSION: MRI assays of vascular endothelial leakiness using new PEG-core, (Gd-DOTA)-conjugated macromolecular contrast agents proved applicable for the differentiation of human breast cancer from normal soft tissue.
  • [MeSH-major] Contrast Media. Gadolinium. Heterocyclic Compounds. Magnetic Resonance Imaging. Neoplasms, Experimental / diagnosis. Organometallic Compounds
  • [MeSH-minor] Animals. Breast Neoplasms / diagnosis. Endothelium, Vascular. Female. Humans. Neoplasm Transplantation. Rats. Rats, Nude. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219614.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 082923; United States / NCI NIH HHS / CA / R01 CA 103850
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


54. Li EX, Wu YY, Shi F, Wu Y, Guo JJ, Dong DF: [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):522-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues].
  • OBJECTIVE: To investigate the relationship between serum VEGF (sVEGF) level and VEGF, COX-2 and MVD expression in breast cancer, and to discuss their role in angiogensis of breast cancer.
  • METHODS: sVEGF level was detected by ELISA in 68 preoperative breast cancer, 35 benign breast disease and 20 healthy women.
  • The expression of VEGF, COX-2 and MVD was detected by immunohistochemical method in tissues of breast cancer and breast benign diseases, and to analyze the relationship of sVEGF, VEGF, COX-2 and MVD. RESULTS:.
  • (1) sVEGF level in preoperative breast cancers was 306.51 pg/ml (interquartile range from 190.44 to 442.04 pg/ml), in benign diseases was 150.82 pg/ml (interquartile range from 82.36 to 212.34 pg/ml), and in healthy control was 105.93 pg/ml (interquartile range from 78.54 to 157.77 pg/ml).
  • The sVEGF level of preoperative breast cancer group was significantly higher than that of breast benign disease group and healthy women (P = 0.001). (2) The VEGF expression positive rate in breast cancer (67.65%) was significantly higher than that in breast benign disease (44.12%) (P = 0.015).
  • The COX-2 expression positive rate in breast cancer (42.86%) was significantly higher than that in breast benign disease (11.43%) (P = 0.002). (3) the COX-2 expression positive rate in sVEGF high level patients (56.00%) was significantly higher than that in sVEGF normal level patients (11.11%) (P = 0.024), and MVD in sVEGF high level patients (27.32 +/- 3.40) was also higher than that in sVEGF normal level patients (15.31 +/- 6.16) (P = 0.011). (4) The sVEGF level (322.09 +/- 79.31) of 68 breast cancer patients whose VEGF was positive in breast cancer tissues was significantly higher than that in VEGF negative group (222.47 +/- 73.53) (P = 0.017). (5) The COX-2 expression positive rate in VEGF positive expression group (65.21%) was significantly higher than that in VEGF negative expression group (18.18%) (P = 0.017).
  • CONCLUSION: sVEGF level in breast cancer is significantly higher than that in breast benign disease and healthy women, and is correlated with the expression of COX-2 and MVD in breast cancer tissues.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Cyclooxygenase 2 / metabolism. Microvessels / pathology. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Female. Fibroadenoma / blood. Fibroadenoma / blood supply. Fibroadenoma / metabolism. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069633.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


55. Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G: Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res; 2007 Feb;125(2):137-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
  • BACKGROUND & OBJECTIVE: In breast cancer, the HER-2/neu gene is amplified in 20-30 per cent of cases.
  • Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and thus might help in management of the disease.
  • The present study was therefore to estimate the serum HER-2/neu levels in breast cancer patients and associate with other prognostic factors.
  • METHODS: Serum HER-2/neu levels were studied in 207 patients with cancer breast, 15 benign breast diseases (BBD) and 175 age-matched healthy controls.
  • INTERPRETATION & CONCLUSION: HER-2/neu serum test could be done more frequently in women with breast cancer irrespective of the hormone receptor status, to suggest modifications in systemic adjuvant therapy, including possibly the use of Herceptin.
  • [MeSH-major] Breast Neoplasms / diagnosis. Receptor, ErbB-2 / blood
  • [MeSH-minor] Age Factors. Female. Gene Expression Regulation, Neoplastic. Humans. India. Logistic Models. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431282.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie; 2007 Feb;30(1-2):14-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.
  • BACKGROUND: We investigated the hypermethylation status in serum of sporadic breast cancer patients.
  • MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic breast cancer patients was examined by methylation-specific PCR (MSP) assay.
  • Normal and benign tissue and serum control DNA were also examined to determine the specificity of hypermethylation.
  • RESULTS: Hypermethylation of 1 or more genes was found in 36/38 (95%) of sporadic breast cancers.
  • No methylated products of BRCA1, p16 and 14-3-3sigma were observed in serum DNA from healthy women and patients with benign tissue specimens.
  • A gene unmethylated in the tumor DNA was always found to be unmethylated in matched serum DNA.
  • CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic breast cancer and can be detected in serum DNA.
  • It signifies that serum-based hypermethylation screening may enhance early detection of sporadic breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Breast Neoplasms / blood. Breast Neoplasms / genetics. DNA Methylation. Genes, Tumor Suppressor
  • [MeSH-minor] 14-3-3 Proteins. Adult. Aged. Cyclin-Dependent Kinase Inhibitor p16 / blood. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis / methods. Exonucleases / blood. Exonucleases / genetics. Exoribonucleases. Female. Humans. Middle Aged. Neoplasm Proteins / blood. Neoplasm Proteins / genetics. Reproducibility of Results. Sensitivity and Specificity. Ubiquitin-Protein Ligases / blood. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264521.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


58. Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ: Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol; 2007 Jan;31(1):129-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
  • Retraction artifact resulting in clear spaces around tumor cell nests is frequently seen in histologic material and may present difficulty in their differentiation from lymphovascular invasion.
  • We noticed that retraction artifact seemed to be more common around groups of breast cancer cells compared with benign acini, and when extensively present, metastasis to axillary lymph nodes was often seen.
  • Thus, we performed a study of 304 cases of stage pT1 and pT2 breast carcinomas to test our hypothesis that extensive retraction artifact in tumors correlates with lymphatic spread and outcome.
  • Tumors were evaluated to determine the presence and extent of retraction artifact around tumor cell nests and the presence of lymphatic invasion.
  • The extent of retraction artifact in tumors was correlated with clinicopathologic tumor features and patient outcome.
  • The extent of retraction artifact showed a significant correlation with tumor size, histologic type, histologic grade, presence of lymphovascular invasion, and nodal metastasis.
  • We propose that the apparent retraction of the stroma from cells of invasive breast carcinoma on routine histologic sections is not a phenomenon merely due to inadequate fixation as currently believed.
  • Rather, it likely signifies important biologic changes that alter tumor-stromal interactions and contribute to lymphatic spread and tumor progression.
  • [MeSH-major] Artifacts. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histocytological Preparation Techniques. Lymph Nodes / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. ROC Curve. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197929.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


59. Uygun K, Kocak Z, Altaner S, Cicin I, Tokatli F, Uzal C: Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer. Yonsei Med J; 2006 Aug 31;47(4):578-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic metastasis from carcinoma of the breast that mimics a primary intestinal cancer.
  • Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic.
  • We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a through review of English language medical literature.
  • Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Intestinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):3014-6 [11051411.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):463-4 [12099661.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Surg Oncol. 1979;11(3):193-205 [459515.001]
  • [Cites] Dis Colon Rectum. 1988 May;31(5):401-2 [3366041.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):181-7 [2910416.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):365-9 [1514536.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Med Klin (Munich). 1992 Dec 15;87(12):631-6 [1287424.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):681-2 [10919011.001]
  • (PMID = 16941751.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687742
  •  go-up   go-down


60. Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P: Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer; 2006 Aug 7;95(3):347-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
  • The aim of this study was to investigate the expression of the protein tyrosine phosphatases (PTP) PRL-1, PRL-2, and PRL-3 in human breast cancer and to evaluate its clinical and prognostic significance.
  • PRL-PTP mRNA expression was examined in malignant (n = 7) and nonmalignant (n = 7) cryoconserved breast tissue samples as well as in eight breast cancer cell lines by RT-PCR.
  • Furthermore, protein expression of PRL-3 was analysed semiquantitatively by immunohistochemistry in ductal breast carcinoma in situ (n = 135) and invasive breast cancer (n = 147) by use of tissue microarray technology (TMA).
  • In 24 lymph node-positive patients we selected the corresponding lymph node metastases for analysis of PRL-3 expression, and a validation set (n = 99) of invasive breast cancer samples was examined.
  • PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue.
  • Staining of TMAs showed PRL-3 expression in 85.9% ductal carcinoma in situ and 75.5% invasive breast carcinomas.
  • Analysis of survival parameters revealed a shorter disease-free survival (DFS) in patients with PRL-3-positive carcinomas, and in particular a significantly shorter DFS in nodal-positive patients with PRL-3 overexpressing tumours as compared to PRL-3-negative breast carcinomas (66+/-7 months (95% CI, 52-80) vs 97+/-9 months (95% CI, 79-115); P = 0.032).
  • Our results suggest that PRL-3 might serve as a novel prognostic factor in breast cancer, which may help to predict an adverse disease outcome.
  • [MeSH-major] Breast Neoplasms / genetics. Cell Cycle Proteins / genetics. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Protein Tyrosine Phosphatases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Follow-Up Studies. Gene Expression Profiling. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / genetics. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):945-51 [14737124.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Feb;49(2):91-107 [15012971.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2393-400 [15073116.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1630-7 [15117985.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114 [11166583.001]
  • [Cites] Breast Cancer Res Treat. 2001 Apr;66(3):201-8 [11510691.001]
  • [Cites] Oncology. 2001;61 Suppl 2:67-72 [11694790.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46659-68 [12235145.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1255-64 [12516958.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] Dev Biol. 2003 May 1;257(1):205-19 [12710968.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jul;129(7):375-82 [12884024.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Hum Genet. 1995 Nov;96(5):532-8 [8529999.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2013-6 [8616842.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):455-8 [9291439.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):951-60 [15753989.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1653-61 [16275986.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1569-83 [16148022.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1173-9 [16210009.001]
  • (PMID = 16832410.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A1 protein, human; EC 3.1.3.48 / PTP4A2 protein, human; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2360632
  •  go-up   go-down


61. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


62. Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC: The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res; 2005;7(6):R871-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
  • INTRODUCTION: Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-alpha (ER-alpha), occur during breast cancer development.
  • This mutation was initially reported in one-third of hyperplastic benign breast lesions, although several recent studies failed to detect it in benign or malignant breast tissues.
  • METHODS: We screened 653 microdissected, newly diagnosed invasive breast tumors from patients in the Carolina Breast Cancer Study, a population-based case-control study of breast cancer in African American and white women in North Carolina, for the presence of the ER-alpha A908G mutation by using single-strand conformational polymorphism (SSCP) analysis and 33P-cycle sequencing.
  • RESULTS: We detected the ER-alpha A908G mutation in 37 of 653 (5.7%) breast tumors.
  • The ER-alpha A908G mutation was found more frequently in higher-grade breast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
  • CONCLUSION: This population-based study, the largest so far to screen for the ER-alpha A908G mutation in breast cancer, confirms the presence of the mutant in invasive breast tumors.
  • The mutation was associated with higher tumor grade and mixed lobular/ductal breast tumor histology.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7 [10619354.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7 [10377423.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1405-7 [9973633.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1225-8 [9592178.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R113-8 [15642159.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9199-208 [15604293.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):869-98 [15583021.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):427-33 [10688862.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):733-6 [11072241.001]
  • [Cites] Breast Cancer. 2003;10(1):70-3 [12525766.001]
  • [Cites] Breast Cancer Res Treat. 2004 Apr;84(3):289-92 [15026626.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):51-4 [15034868.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):597-605 [15193262.001]
  • [Cites] Epidemiol Rev. 1993;15(1):17-35 [8405201.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2371-4 [9215322.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 15;25(22):4500-4 [9358158.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):363-72 [9449239.001]
  • (PMID = 16280033.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / 5-P50-CA58223
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Estrogen Receptor alpha
  • [Other-IDs] NLM/ PMC1410768
  •  go-up   go-down


63. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • Expression of CK19 mRNA was positively correlated with tumor size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


64. Sanders ME, Page DL, Simpson JF, Schuyler PA, Dale Plummer W, Dupont WD: Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer; 2006 Apr 1;106(7):1453-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
  • BACKGROUND: Radial scars (RS) are benign breast lesions that have been implicated as independent risk factors for invasive breast carcinoma (IBC).
  • METHODS: A retrospective cohort study of 9556 women who underwent biopsy between 1950-1986 and enrolled in the Nashville Breast Cohort was performed to investigate the association between RS in a benign breast biopsy and the risk of IBC.
  • Although the presence of RS in a benign breast biopsy mildly elevates the risk of IBC risk, the current analysis indicated that this risk can be largely attributed to the category of coexistent PD.
  • [MeSH-major] Breast / pathology. Breast Diseases / complications. Breast Neoplasms / etiology. Carcinoma / etiology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Hyperplasia / complications. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16502407.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA68485; United States / NCI NIH HHS / CA / P50-CA098131; United States / NCI NIH HHS / CA / R01-CA50468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


66. Engohan-Aloghe C, Hottat N, Cosaert J, Boutemy R, Fayt I, Noël JC: Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases. Cytopathology; 2010 Jun;21(3):161-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of accuracy of fine needle aspiration cytology in BI-RADS3 category breast lesions: cytohistological correlation in 337 cases.
  • OBJECTIVE: To evaluate the accuracy of fine needle aspiration cytology (FNAC) in BI-RADS3 breast lesions.
  • RESULTS: The histological diagnosis showed that 88% (59/67) of BI-RADS3 breast lesions were benign.
  • However, the correlation between cytology and histology showed that most of these lesions were benign and that finally FNAC remains a useful and accurate test in the management of these lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744191.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S: FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biol Pharm Bull; 2009 Jul;32(7):1148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
  • FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers.
  • Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors.
  • Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines.
  • Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA.
  • These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
  • [MeSH-major] Breast Neoplasms / metabolism. Cell Proliferation. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Alignment. Transfection

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571376.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


68. Akin M, Bozkirli B, Leventoglu S, Unal K, Kapucu LO, Akyurek N, Sare M: Liver schwannoma incidentally discovered in a patient with breast cancer. Bratisl Lek Listy; 2009;110(5):298-300
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver schwannoma incidentally discovered in a patient with breast cancer.
  • BACKGROUND: Benign schwannomas, also referred to as neurilemomas, neurinomas, and perineural fibroblastomas, are encapsulated nerve sheath tumors.
  • We present a case of liver schwannoma, incidentally found in a patient with breast cancer.
  • CASE: A 66-year-old female consulted her physician for a mass she palpated on her left breast.
  • An USG-guided biopsy was performed and the histo-pathological examination revealed a "peripheral nerve sheath tumor".
  • The tumor resected from the liver was 5 x 4 x 3 cm, yellowish, soft, and capsulated tumor.
  • The tumor was diagnosed as benign liver schwannoma.
  • CONCLUSION: Schwannomas are benign, encapsulated neoplasms.
  • Symptoms and signs vary depending on the anatomical site and the size of the neoplasm; however, most schwannomas present as an asymptomatic or painless mass.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Liver Neoplasms. Neoplasms, Multiple Primary. Neurilemmoma
  • [MeSH-minor] Aged. Female. Humans


69. Oba M, Sasaki M, Ii T, Hoso M, Ajisaka H, Matsuki N, Miwa K: A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma. Breast Cancer; 2009;16(2):141-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma.
  • Lymphocytic mastopathy is a benign breast disease characterized by dense fibrosis, lobular atrophy, and aggregates of lymphocytes in a periductal and perivascular distribution.
  • Here, we report a case of the disease clinically and radiologically mimicking primary breast neoplasms.
  • The patient was a 50-year-old woman without diabetes who presented with two firm lumps in her right breast.
  • Breast imaging findings from mammography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), respectively, revealed an abnormal appearance suspicious of malignancy.
  • A core-needle biopsy specimen showed atypical accumulation of lymphoid cells, which was not easy to differentiate from primary breast lymphomas.
  • Histological examination of a surgically obtained specimen showed characteristic appearance of lymphocytic mastopathy, which predominantly consisted of B-lymphocytes.
  • In our case, it was difficult to distinguish this entity from breast cancer or low-grade B-cell lymphoma without surgical biopsy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphocytes / pathology. Lymphoma / diagnosis. Mastitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769994.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A: Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. Int J Clin Oncol; 2008 Jun;13(3):252-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan.
  • BACKGROUND: With the development of the CellSearch System, it has become possible to measure circulating tumor cell (CTC) levels with high reproducibility, and the CTC test is currently being used clinically for patients with metastatic breast cancer in the United States.
  • METHODS: Using the CellSearch System, CTC levels were evaluated in 57 healthy individuals and patients with benign breast disease; 30 patients with primary breast cancer (stages 1-3); and 38 patients with metastatic breast cancer.
  • Then, the patients with metastatic breast cancer were divided into two groups, using a cutoff score of 5 CTCs per 7.5 ml blood, and progression-free survival (PFS) and overall survival (OS) were compared in the two groups.
  • RESULTS: When the clinical cutoff score was set at 2 CTCs per 7.5 ml blood, 0% of the healthy individuals and patients with benign breast disease (0/57), 3.3% of the patients with primary breast cancer (1/30), and 50% of the patients with metastatic breast cancer (19/38) were identified as as having 2 CTCs per 7.5 ml blood.
  • CONCLUSION: As concluded in a similar clinical trial in the United States, for patients with breast cancer, measuring CTC levels can be both an accurate indicator of metastases and an important measure of patient prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Cell Count. Cell Separation / instrumentation. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24 [16857794.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12 (21):6403-9 [17085652.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1420-30 [15735118.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6897-904 [15501967.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):920-8 [17289886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8 [15194824.001]
  • (PMID = 18553236.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


71. Dugina VB, Chipysheva TA, Ermilova VD, Gabbiani D, Chaponnier C, Vasil'ev IuM: [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells]. Arkh Patol; 2008 Mar-Apr;70(2):28-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells].
  • The distribution of beta- and gamma-cytoplasmic actins was compared in the normal cells and dysplastic malignant breast epithelial cells.
  • The authors' findings suggest that specific monoclonal antibodies to beta- and gamma-cytoplasmic actins may be used as supplementary markers that can differentiate benign and malignant breast neoplasms.
  • [MeSH-major] Actins / metabolism. Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Fibrocystic Breast Disease / metabolism. Mammary Glands, Human / metabolism. Neoplasm Proteins / metabolism. Papilloma / metabolism
  • [MeSH-minor] Female. Humans. Protein Isoforms / metabolism. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540438.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


72. Moore A, Hendon A, Hester M, Samayoa L: Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis? Breast J; 2008 May-Jun;14(3):293-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis?
  • Secondary angiosarcomas, although rare, are aggressive tumors that can develop in breast tissue that has undergone prior radiation therapy.
  • We present three cases of secondary angiosarcoma of the breast in the setting of prior breast irradiation.
  • Imaging findings include cutaneous nodules and progressive skin or trabecular thickening in an area of the breast separate from the patient's original breast carcinoma.
  • These imaging findings may enable the radiologist to suggest this diagnosis, even when the clinical presentation is more benign.
  • [MeSH-major] Breast Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Radiation-Induced / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476885.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve SS: Prostanoid receptor EP1 expression in breast cancer. Mod Pathol; 2008 Jan;21(1):15-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostanoid receptor EP1 expression in breast cancer.
  • In this study, we analysed the expression of EP1 in normal and malignant breast tissues.
  • Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses.
  • Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer.
  • EP1 expression was demonstrated in human breast cancer by immunohistochemistry.
  • Expression of EP1 is frequently seen in human breast cancers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Receptors, Prostaglandin E / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Nucleus / chemistry. Cyclooxygenase 2 / analysis. Cytoplasm / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Receptors, Prostaglandin E, EP1 Subtype. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906615.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37403; United States / NIAMS NIH HHS / AR / K08 AR
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PTGER1 protein, human; 0 / Ptger1 protein, mouse; 0 / Ptger1 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP1 Subtype; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


74. Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY: Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol; 2007 Dec;33(12):1873-81
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.
  • Accurate assessment of tumor size is necessary when selecting patients for breast-conserving surgery.
  • In the study of breast contrast-enhanced ultrasound (CEUS), we found that tumor size discrepancy between CEUS and conventional ultrasound (US) existed in some breast lesions, for which the reasons are not clear.
  • Breast CEUS examinations were performed in 104 patients with breast lesions.
  • The measurement of the 104 breast tumors on conventional US was obtained and compared with the measurement on CEUS.
  • A difference in measuring tumor size of >3 mm for tumors up to 1.7 cm and 4 mm for tumors >or=1.7 cm, was defined as a significant discrepancy between conventional US and CEUS.
  • The histopathological examination of size discrepancy was performed and the margin characteristics of breast cancers with larger measurements were compared with those with unchanged measurements.
  • Among the 104 lesions (43 malignant, 60 benign, 1 borderline), the size of 27 breast cancers and one granulomatous mastitis appeared larger at CEUS.
  • Pathologic examinations of the region corresponding to the measurement discrepancy were mainly ductal carcinomas in situ (DCIS), invasive carcinoma with a DCIS component, adenosis with lobular hyperplasia in breast cancers and inflammatory cell infiltration in one granulomatous mastitis.
  • Well-defined margin characteristics were significantly different between breast cancers with larger measurements at CEUS and those with unchanged measurements of size (p = 0.002), whereas no significant difference was found between the two groups in ill-defined, spiculated, hyperechoic halo, microlobulated and angulated margins (p = 0.463, 0.117, 0.194, 0.666 and 0.780, respectively).
  • This initial study suggests that significant discrepancy of breast lesion measurement between conventional US and CEUS is more likely presented in breast cancer than benign lesions.
  • The pathologic findings corresponding to the region of size increased at CEUS are malignant in most malignant lesions and benign in benign lesions.
  • It is difficult to predict whether the size measurement of the breast cancer increases at CEUS based on the margin characteristics showed on conventional US.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Breast Diseases / ultrasonography. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neoplasm Staging. Phospholipids. Reproducibility of Results. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686569.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


75. Cejas P, García-Cabezas MA, Casado E, Belda-Iniesta C, De Castro J, Fresno JA, Sereno M, Barriuso J, Espinosa E, Zamora P, Feliu J, Redondo A, Hardisson DA, Renart J, González-Barón M: Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma. Free Radic Res; 2007 Jun;41(6):681-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospholipid hydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma.
  • To investigate the possible relationship between PHGPx and human cancer we have quantified PHGPx expression levels by real-time quantitative PCR and immunohistochemistry in tissue samples of human breast invasive ductal carcinoma from 34 patients compared with their own controls of benign breast tissue.
  • The results showed that PHGPx expression levels are downregulated in poorly differentiated (grade 3) breast invasive ductal carcinoma (P = 0.0043).
  • PHGPx expression levels decreased gradually with tumor grade from grade 1 to grade 3.
  • These results suggest that PHGPx downregulation could be related with a poorer prognosis in breast invasive ductal carcinoma.
  • [MeSH-major] Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Cell Differentiation. Gene Expression Regulation, Enzymologic. Glutathione Peroxidase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Down-Regulation. Female. Humans. Immunoenzyme Techniques. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516241.001).
  • [ISSN] 1071-5762
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 1.11.1.12 / phospholipid-hydroperoxide glutathione peroxidase; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


76. Granić M, Oprić D, Pupić G, Babić D, Ivanović N, Nikolić D, Dikić S, Oprić S: [Surgical methods for the treatment of breast phyllodes tumors--a report of 319 cases]. Acta Chir Iugosl; 2006;53(1):57-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical methods for the treatment of breast phyllodes tumors--a report of 319 cases].
  • Breast phyllodes tumors (FT) belong the fibroapitelial group of breast tumors arising in terminal ductulo-lobular unit (TDLU).
  • Their incidence do not exceed 1% of all breast tumors.
  • Biologicaly they can be divided into benign, borderline and malignant group.
  • Incomplete tumor excision can be the reason for local reccurence.
  • METHODS: We analyzed histopathology features of 319 FT of the breast surgicaly removed on Departement of surgery Institut of oncology and radiology of Serbia between 1.1.1985.
  • -31.12.1994. Retrospective study of surgical treatment 84 patients with FT of the breast (69 benign, 4 borderline and 11 malignant) and 5 year follow up after surgery we analysed.
  • RESULTS: local reccurence after surgery was found in 17 (20,2 %) patients(14 benign , 2 borderline and 1 malignant FT), pulmonary metastases in 6 (7,1%) patients with malignant FT.
  • CONCLUSION: According to biological behavior we propose wide excision for benign and borderline forms and simple mastectomy for malignant FT, and voluminous benign and borderline forms.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989148.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


77. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


78. Zhou Y, Inaba S, Liu J: Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment. Int J Oncol; 2006 Jul;29(1):289-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
  • Anti-microtubule drugs that cause mitotic arrest and subsequent apoptosis of cancer cells are frequently used to treat breast cancer patients with advanced or metastatic diseases.
  • Our previous studies have demonstrated that the neuronal protein, synuclein-gamma (SNCG), plays oncogenic roles in breast carcinogenesis and is abnormally expressed at high levels in advanced and metastatic breast carcinomas but not expressed in normal or benign breast tissues.
  • In this study, we show that responses of 12 breast cancer cell lines to paclitaxel-induced mitotic arrest and cytotoxicity highly correlate with SNCG expression status.
  • Moreover, we demonstrate that down-regulation of SNCG expression directly increased the effectiveness of anti-microtubule drug-induced cytotoxicity in breast cancer cells without altering cell responses to doxorubicin.
  • These new findings suggest that SNCG expression in breast carcinomas is probably a causal factor contributing to the poor patient response to paclitaxel treatment.
  • [MeSH-major] Antimitotic Agents / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Paclitaxel / pharmacology. gamma-Synuclein / metabolism
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Gene Silencing. Humans. Inhibitory Concentration 50. Oncostatin M / pharmacology. RNA, Antisense / genetics. RNA, Antisense / metabolism. Time Factors. Transfection. Tumor Stem Cell Assay. Urea / analogs & derivatives. Urea / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. UREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773211.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3-bromopropionylamino benzoylurea; 0 / Antibiotics, Antineoplastic; 0 / Antimitotic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Neoplasm Proteins; 0 / RNA, Antisense; 0 / SNCG protein, human; 0 / gamma-Synuclein; 106956-32-5 / Oncostatin M; 80168379AG / Doxorubicin; 8W8T17847W / Urea; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


79. Kwon MS, Kim SJ, Lee SY, Jeong JH, Lee ES, Kang HS: Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue. Oncol Rep; 2006 Jan;15(1):27-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue.
  • This study was intended to evaluate the methylation status and transcriptional activity of SULT1A1 in breast cancer tissue (n=56), benign breast tissue (n=20) and morphologically normal breast tissue (n=20), examined by bisulfite genomic sequencing and reverse transcription (RT)-PCR.
  • As a result, the methylation of the proximal promoter (P1) was identified in 64.3% of breast carcinomas, 15% of normal and 20% of benign breast tissues.
  • In terms of the distal promoter (P0), 32 of 56 cancer tissues (57.1%) were methylated, while 4 normal (20%) and 6 benign tissues (30%) were methylated.
  • Breast cancer tissue showed a higher methylation rate of SULT1A1 than normal and benign tissue at both P1 (p=0.001) and P0 (p=0.006) promoters with statistical significance.
  • Furthermore, cancer tissue showed a higher methylation density rate than normal and benign breast tissue at both P1 and P0 promoters (P1, p=0.001; P0, p=0.001).
  • Although the number of samples was relatively small, our results suggest that DNA methylation in the SULT1A1 gene appears to be present in breast tissue including cancer and methylation significantly impacts transcriptional silencing of the gene.
  • In addition, it can be suggested that progressive SULT1A1 methylation within the promoter area of the gene occurs during breast carcinogenesis.
  • [MeSH-major] Arylsulfotransferase / genetics. Breast Neoplasms / enzymology. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing
  • [MeSH-minor] CpG Islands. Epigenesis, Genetic. Female. Genes, Neoplasm / genetics. Humans. Promoter Regions, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328031.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


80. Arpino G, Laucirica R, Elledge RM: Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med; 2005 Sep 20;143(6):446-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant and in situ breast disease: biology and clinical implications.
  • Most types of invasive breast cancer are thought to evolve over long periods from specific preexisting benign lesions.
  • Of the many types of benign entities found in the human breast, only a few have clinically significant premalignant potential.
  • The development of modern molecular genetic techniques has allowed breast cancer researchers to clarify the multistep model of breast carcinogenesis.
  • Options for breast cancer risk reduction and prevention are available.
  • [MeSH-major] Breast / pathology. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Disease Progression. Female. Humans. Hyperplasia / pathology. Neoplasm Invasiveness. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172443.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA30195; United States / NCI NIH HHS / CA / P50 CA58183; United States / NCI NIH HHS / CA / U-19 CA86809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


81. Izzo L, Stasolla A, Basso L, Caputo M, Kharrub Z, Marini M, Mingazzini P, Fiori E, Galati G, D'Aprile MR, Mele LL, Marini M: Characterization of tumoral lesions of the breast: preliminary experience with multislice spiral CT. J Exp Clin Cancer Res; 2005 Jun;24(2):209-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of tumoral lesions of the breast: preliminary experience with multislice spiral CT.
  • The aim of the present study was to validate low dose Multislice Spiral Computed Tomography (MSCT) in the diagnosis of breast lesions.
  • Fourteen patients with mammographic and ultrasound findings suspect of malignant neoplasm underwent dynamic MSCT of the breast under basal conditions and 1, 3, and 6 minutes after intravenous injection of iodinated contrast medium.
  • A correct diagnosis was achieved by MSCT in 7/8 malignant lesions, and in 6/6 benign lesions.
  • Sensitivity and specificity of MSCT in the diagnosis of malignancy of a lesion were 88% and 100%, respectively.
  • Our results suggest that MSCT is an effective diagnostic method to define suspicious breast lesions, and a valid alternative to Magnetic Resonance Imaging, especially when the latter is not feasible.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Mammography / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Contrast Media / administration & dosage. Female. Humans. Iodine Radioisotopes / administration & dosage. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110753.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes
  •  go-up   go-down


82. Fulciniti F, Mansueto G, Vetrani A, Accurso A, Fortunato A, Palombini L: Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases. Diagn Cytopathol; 2005 Sep;33(3):205-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases.
  • Metaplastic breast carcinoma (MBC) may have a varied presentation on fine-needle cytology samples.
  • Because of the various presentation of MBC on fine-needle cytology samples and the possible influence of needle "sampling" on the cytological specimen, the spectrum of differential diagnoses to be considered may encompass a number of benign and malignant entities, like keratinous subareolar cysts, malignant fibroepithelial lesions with myxo-chondroid stroma, and true sarcomas of the breast, with cartilaginous metaplasia.
  • It is the Authors' feeling that, with optimal samples, the cytomorphological findings of this rare variant of breast carcinoma permit its accurate pre-operative diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sarcoma / metabolism. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078244.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Yang HW, Cao J, Yang NW, Liu JL, Zhang CM, Chen JS, Hong JS, Jiang Y, Su JJ: [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance]. Ai Zheng; 2005 Jul;24(7):842-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance].
  • BACKGROUND & OBJECTIVE: The major cause of death in breast cancer patients is distant metastasis.
  • This study was to explore the expression and significance of small breast epithelial mucin (SBEM) mRNA, the specific marker of breast cancer, in peripheral blood of breast cancer patients.
  • METHODS: Expression of SBEM mRNA in peripheral blood samples from 67 breast cancer patients, 16 benign breast disease patients, and 20 healthy volunteers was detected by nested reverse transcription-polymerase chain reaction (nested RT-PCR).
  • RESULTS: SBEM mRNA was not detected in healthy volunteers and benign breast disease patients.
  • Positive rate of SBEM mRNA was 50.7% (34/67) in breast cancer patients.
  • The expression of SBEM mRNA in peripheral blood was not correlated with patient's age, primary tumor size, pathologic type, and estrogen or progestin receptor status (P0.05).
  • CONCLUSION: SBEM mRNA is specifically expressed in peripheral blood of breast cancer patients, and may be a marker of micrometastasis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Female. Fibroma / metabolism. Fibroma / pathology. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Estrogen / blood. Receptors, Progesterone / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004812.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUCL1 protein, human; 0 / Mucins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


84. Schulz-Wendtland R, Bock K, Aichinger U, de Waal J, Bader W, Albert US, Duda VF: [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?]. Ultraschall Med; 2005 Jun;26(3):209-15
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?].
  • [Transliterated title] Mamma-Sonographie mit 7.5 MHz versus 13 MHz: Ist eine Verbesserung der diagnostischen Sicherheit im Rahmen der komplementären Mammadiagnostik möglich?
  • AIM: Complementary diagnostic methods in early diagnosis of breast cancer are used to increase diagnostic accuracy and minimize unnecessary invasive diagnostic procedures.
  • Aim of the following prospective, open multicenter clinical study was to define the value of high-frequency breast ultrasound with 13 MHZ transducers compared to standard breast ultrasound with 7.5 MHz.
  • METHOD: Data of 810 female patients, aged 45 to 60 years, with 819 suspicious breast lesions evaluated by four participating centres between October 1996 and December 1997.
  • Standardised breast ultrasound was performed uniformly using a AU4 IDEA diagnostic ultrasound system by Esaote-Biomedica in addition to a standardised procedure of clinical examination and standard-2view-mammography.
  • RESULTS: The histopathological evaluation showed 435 benign and 384 malignant findings.
  • High-frequency breast ultrasound (13 MHz) proved to have a higher diagnostic accuracy compared to standard breast ultrasound (7,5 MHz) regardless of tumour size.
  • CONCLUSIONS: We conclude that high-frequency ultrasound is a valueable additive tool especially in the diagnosis of small tumours, improving diagnostic safety and reducing unnecessary invasive diagnostic procedures.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948057.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Szabo-Moskal J, Lasek W, Kozłowska R, Sir J, Serafin Z: [The role of preoperative hooked-wire localization of occult lesions for early detection of breast cancer]. Ginekol Pol; 2005 Jan;76(1):15-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of preoperative hooked-wire localization of occult lesions for early detection of breast cancer].
  • OBJECTIVES: Nonpalpable small lesions, usually few millimeters in diameter, consist an important problem in the early diagnostics of breast cancer.
  • DESIGN: An aim of this paper was an evaluation of usefulness of preoperative hooked-wire localization of such lesions for the detection of breast cancer.
  • RESULTS: Histologic examination of the localized lesions revealed benign changes in 71.2%, atypical ductal hyperplasia in 4.6% and cancer in 24.2%.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Mammography. Middle Aged. Neoplasm Invasiveness. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844561.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


86. Kabukcuoglu F, Kabukcuoglu Y, Tanik C, Sakiz D, Karsidag S: Breast carcinoma metastasis in recurrent myxoid liposarcoma. Pathol Oncol Res; 2009 Sep;15(3):467-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma metastasis in recurrent myxoid liposarcoma.
  • Tumor to tumor metastasis is a rare, but well recognized entity, most commonly involving a carcinoma metastasis to a benign or low grade mesenchymal tumor.
  • A case of breast carcinoma metastasis in a recurrent myxoid liposarcoma is presented in this study.
  • A 52-year-old female patient with a history of breast carcinoma (70% invasive lobular carcinoma and 30% invasive ductal carcinoma) presented with a mass in the right lumbar region.
  • The tumor recurred twice and was reexcised.
  • Microscopic examination of the second recurrence revealed multiple foci of breast carcinoma metastases in myxoid liposarcoma.
  • Both breast carcinoma metastasis and myxoid liposarcoma were immunoreactive for E-cadherin and beta-catenin.
  • To our knowledge, this is the first reported case of breast carcinoma metastasis in myxoid liposarcoma, and the first occurrence of metastasis in a liposarcoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Liposarcoma, Myxoid / pathology. Neoplasms, Second Primary / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Mastectomy. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):171-80 [8554106.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):127-35 [12754635.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):149-55 [16132512.001]
  • [Cites] Cancer. 1968 Sep;22(3):635-43 [5673241.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] Gynecol Oncol. 1996 Sep;62(3):408-10 [8812542.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):222-9 [17058128.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):948-53 [11844068.001]
  • [Cites] Head Neck. 2005 Jan;27(1):76-80 [15565563.001]
  • [Cites] AMA Arch Pathol. 1958 Sep;66(3):293-8 [13570810.001]
  • [Cites] Am J Clin Oncol. 2002 Aug;25(4):414-7 [12151976.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):703-6 [10420227.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] Pathol Int. 2005 Sep;55(9):574-9 [16143033.001]
  • [Cites] Arch Pathol Lab Med. 1980 Jul;104(7):350-4 [6893121.001]
  • [Cites] Pathology. 1999 May;31(2):162-5 [10399174.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):196-8 [2910417.001]
  • [Cites] J Cutan Pathol. 2005 Sep;32(8):561-6 [16115055.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;405(1):155-60 [6438898.001]
  • [Cites] Am J Pathol. 1979 Dec;97(3):623-32 [507194.001]
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):199-202 [10199462.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jan 10;106(1):76-8 [12475587.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1071-8 [12204056.001]
  • (PMID = 18987996.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M: Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):492-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast.
  • PURPOSE: To better identify prognostic factors for local control and survival, as well as the role of different therapeutic options, for phyllodes tumors, a rare fibroepithelial neoplasm of the breast.
  • Tumors were benign in 284 cases (64%), borderline in 80 cases (18%), and malignant in 79 cases (18%).
  • Surgery consisted of breast-conserving surgery (BCS) in 377 cases (85%) and total mastectomy (TM) in 66 cases (15%).
  • Multivariate analysis revealed benign histology, negative margins, and no residual disease (no RD) after initial treatment and RT delivery as independent favorable prognostic factors for local control; benign histology and low number of mitosis for disease-free survival; and pathologic tumor size < or = 3 cm and no tumor necrosis for overall survival.
  • CONCLUSIONS: This study showed that phyllodes tumor patients with no RD after treatment have better local control.
  • Benign tumors have a good prognosis after surgery alone.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Child. Female. Follow-Up Studies. Humans. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931796.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


88. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • GLI1 protein and mRNA, and PTCH1 and sonic hedgehog (SHH) proteins were elevated in 3 of 10 breast cancers; however, PTCH1 transcripts were not consistently increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.
  • Determination as to whether the increase in GLI1 and SHH expression in breast cancer indicates a significant increase in hedgehog signaling will require further evaluation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


89. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


90. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
  • PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.
  • METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.
  • RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.
  • All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.
  • The exceptions were represented by a case of fibroadenoma and the phyllodes tumor, with CD34 positivity and a focal acquisition of SMA; fibrocystic disease with associated apocrine metaplasia adjacent to a squamous carcinoma with loss of CD34 expression and focal acquisition of SMA.
  • CONCLUSIONS: Although there were some exceptions especially when one of the two markers was interpreted separately and in some cases associated with sclerotic stroma, we conclude that the combined expression of CD34 and a-SMA is of potential diagnostic value in the distinction between benign and malignant tumors in some difficult cases.
  • [MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


92. Arentz C, Baxter K, Boneti C, Henry-Tillman R, Westbrook K, Korourian S, Klimberg VS: Ten-year experience with hematoma-directed ultrasound-guided (HUG) breast lumpectomy. Ann Surg Oncol; 2010 Oct;17 Suppl 3:378-83
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year experience with hematoma-directed ultrasound-guided (HUG) breast lumpectomy.
  • Despite these issues, NLBB is still the primary means of identifying nonpalpable lesions in the breast.
  • These patients underwent preoperative core-biopsy diagnosis by ultrasound (US) or stereotactic means.
  • The previous core-biopsy site in 100% of patients was successfully excised using HUG: 152 of 329 (46%) were benign and 177 of 329 (54%) were malignant.
  • was successful in 100% of patients: 88 of 126 (70%) were benign and NLBB 38 of 126 (30%) were malignant; margins were positive in 18 of these 38 (47%).
  • [MeSH-major] Breast Neoplasms / surgery. Breast Neoplasms / ultrasonography. Mastectomy, Segmental. Ultrasonography, Mammary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Female. Follow-Up Studies. Hematoma / pathology. Hematoma / surgery. Hematoma / ultrasonography. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Stereotaxic Techniques. Ultrasonography, Interventional. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853061.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Abdalla FB, Boder JM, Buhmeida A, Elzagheid AI, Collan Y: Image DNA cytometry in FNABs of Libyan breast disease. Anticancer Res; 2010 Jan;30(1):175-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image DNA cytometry in FNABs of Libyan breast disease.
  • This percentage is dependent on the number of examined cells, type of breast cancer, and experience of the examiner.
  • The aim of our study was to estimate the supporting value of image DNA cytometry of FNAB of the breast, and do so by using different sampling methods.
  • MATERIALS AND METHODS: This retrospective study was based on 41 cases with an available histological diagnosis: 18 benign lesions and 23 malignant tumours were examined.
  • The method can be used to increase the cytological sensitivity and specificity in doubtful breast lesions.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA, Neoplasm / analysis. Image Cytometry / methods
  • [MeSH-minor] Aneuploidy. Biopsy, Fine-Needle / methods. Female. Humans. Libya. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150633.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


94. Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T: [Adenoid cystic carcinoma of the breast]. Cancer Radiother; 2009 Jul;13(4):323-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinome adénoïde kystique du sein.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm, accounting for only 0.1% of all malignant breast tumours.
  • The clinical criteria is not specific and the radiographic examination showed a benign-appearing tumour.
  • The preoperative diagnosis is possible with fine-needle aspiration cytology.
  • The diagnosis is made by histological examination, presented a difficult differential diagnosis with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
  • Compared to other locations, adenoid cystic carcinoma of the breast has a favorable prognosis.
  • The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type of breast tumour.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464219.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


95. Al-Thobhani AK, Raja'a YA, Noman TA, Al-Romaimah MA: Profile of breast lesions among women with positive biopsy findings in Yemen. East Mediterr Health J; 2006 Sep;12(5):599-604
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of breast lesions among women with positive biopsy findings in Yemen.
  • This study described the profile of breast pathology based on records from a reference histopathology laboratory in Yemen of 773 women with positive biopsy or mastectomy findings.
  • Benign lesions were found in 79.9% of cases.
  • Fibroadenoma was the most prevalent lesion (30.0%) with a mean age at presentation of 22.2 years, followed by fibrocystic disease (27.4%) and breast inflammation (13.1%).
  • [MeSH-major] Biopsy. Breast Neoplasms / epidemiology. Fibrocystic Breast Disease / epidemiology. Mastitis / epidemiology
  • [MeSH-minor] Adenoma / epidemiology. Adult. Age Distribution. Carcinoma, Ductal, Breast / epidemiology. Female. Fibroadenoma / epidemiology. Humans. Incidence. Mastectomy. Neoplasm Staging. Population Surveillance. Prevalence. Retrospective Studies. Risk Factors. Yemen / epidemiology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333799.001).
  • [ISSN] 1020-3397
  • [Journal-full-title] Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ
  • [ISO-abbreviation] East. Mediterr. Health J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


96. Beyrouti MI, Beyrouti R, Khabir A, Ben Amar M, Frikha F, Dhieb N, Damak D, Abid M, Affes N, Boujelben S, Frikha M: [Fibrocystic mastopathy and cancer of the breast. About 111 cases]. Tunis Med; 2006 Oct;84(10):626-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibrocystic mastopathy and cancer of the breast. About 111 cases].
  • [Transliterated title] Mastopathies fibrokystiques et cancers du sein. A propos de 111 cas.
  • METHODS: This work is a retrospective survey of 111 observations of isolated fibrocystic mastopathies or associated to a breast cancer among 542 women admitted for tumor of the breast during one period of 13 active years from 1991 to 2003.
  • The diagnosis has been gotten by anatomo-pathologic exam in 95.5% (106 cas) on the operative piece and 4.5% (5 cas) on a material of biopsy.
  • RESULTS: The fibrocystic mastopathy represented 30% of the set of the benign tumors of the breast.
  • They were associated to a breast cancer in 45 cases (40.5%).
  • The isolated benign fibrocystic mastopathy was observed in 66 cases with a middle age of 37 years, whereas the shapes associated to a breast carcinoma were noted in 45 cases.
  • CONCLUSION: The discovery of a mastopathy must search a luteal failure and risk factors of breast cancer notably a proliferative shape of mastopathy with atypies.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Fibrocystic Breast Disease
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Breast / pathology. Chi-Square Distribution. Data Interpretation, Statistical. Female. Humans. Menopause. Middle Aged. Neoplasm Staging. Parity. Predictive Value of Tests. Pregnancy. Retrospective Studies. Risk. Risk Factors. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193854.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


97. Tafuri LS, Rocha GF, Gobbi H: Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol; 2006;7:29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer.
  • BACKGROUND: Hyperplasia of usual type (HUT) is a common proliferative lesion associated with a slight elevated risk for subsequent development of breast cancer.
  • The aim of this study was to analyze the expression of cell cycle related proteins in HUT of breast specimens of patients with and without breast cancer, and compare this expression with areas of invasive carcinomas.
  • RESULTS: Immunohistochemical evaluation was performed using antibodies against cell cycle related proteins ER, PR, p53, p21, p63, and Ki-67 in hyperplasia of usual type (HUT) in specimens of aesthetic reduction mammaplasty (ARM), in specimens of mammaplasty contralateral to breast cancer (MCC), and in specimens of invasive mammary carcinomas (IMC) presenting HUT in the adjacent parenchyma.
  • We also found cytoplasmic expression of p21 in benign hyperplastic lesions and in neoplastic cells of IMC.
  • CONCLUSION: Our data failed to demonstrate different expression of cell cycle related proteins in HUT from patients with and without breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Cycle Proteins / physiology. Hyperplasia / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Ki-67 Antigen / metabolism. Membrane Proteins / metabolism. Menopause / physiology. Middle Aged. Neoplasm Invasiveness / pathology. Proto-Oncogene Proteins p21(ras) / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1992 Feb 19;267(7):941-4 [1734106.001]
  • [Cites] Histopathology. 2005 Nov;47(5):458-66 [16241993.001]
  • [Cites] Br J Cancer. 1993 Sep;68(3):540-8 [8102535.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • [Cites] J Clin Pathol. 1995 Jul;48(7):611-5 [7560165.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):2049-52 [8562164.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):208-15 [8688323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1811-5 [10595909.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Pathol Res Pract. 2000;196(7):489-501 [10926327.001]
  • [Cites] Breast Cancer Res Treat. 2000 May;61(1):33-43 [10930088.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):104-10 [11082280.001]
  • [Cites] J Pathol. 2001 Mar;193(3):333-8 [11241412.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):866-70 [11684722.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Breast Cancer. 2002;9(3):216-9 [12185332.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):214-20 [12610102.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R242-9 [14580260.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1143-50 [15492807.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):518-29 [2297643.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):37-42 [9428781.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Pathol. 1998 Mar;184(3):265-71 [9614378.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):891-6 [9626358.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1591-9 [9816338.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1539-45 [9865845.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1223-34 [10064589.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):857-9 [15499614.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6949-52 [1458485.001]
  • (PMID = 16869981.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC1563460
  •  go-up   go-down


98. Fabre Demard N, Boulet P, Prat X, Charra L, Lesnik A, Taourel P: [Breast MRI in invasive lobular carcinoma: diagnosis and staging]. J Radiol; 2005 Sep;86(9 Pt 1):1027-34
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast MRI in invasive lobular carcinoma: diagnosis and staging].
  • [Transliterated title] Apport de l'IRM dans le diagnostic et le bilan d'extension des cancers lobulaires infiltrants.
  • PURPOSE: To assess the use of breast MRI for the diagnosis and staging of invasive lobular carcinoma and its impact on surgical management.
  • For 3 patients MRI lead to biopsy of benign lesions but improved the surgical management in the 8 cases of new cancers: wider excision for 3 cases, planned breast conservation converted to mastectomy in 3 cases and excision of contralateral lesion in 2 cases.
  • CONCLUSION: Breast MRI is useful in diagnosis, staging and surgical management of invasive lobular breast carcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Humans. Image Enhancement. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Staging. Patient Care Planning. Retrospective Studies. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224343.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


99. Bonaventure T, Cormier B, Lebas P, Bonneau C, Michenet P: [Benign papilloma: is US-guided vacuum-assisted breast biopsy an alternative to surgical biopsy?]. J Radiol; 2007 Sep;88(9 Pt 1):1165-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign papilloma: is US-guided vacuum-assisted breast biopsy an alternative to surgical biopsy?].
  • [Transliterated title] Les macrobiopsies échoguidées assistées par le vide peuvent-elles constituer une alternative à l'exérèse chirurgicale de papillome bénin?
  • The purpose of this study is to assess the value of US guided vacuum-assisted breast biopsy compared to surgery for management of intraductal papilloma.
  • This retrospective study included 13 patients with hypoechoic nodular lesion corresponding to small benign intraductal papillomas on biopsy and visible by US.
  • Vacuum-assisted tumor removal was considered total for all 13 lesions.
  • Two patients had tumor recurrence at 22 and 28 months respectively.
  • US-guided vacuum-assisted excision of small benign tumors such as solitary intraductal papillomas appears to be an alternative to surgical biopsy.
  • Because of the large volume of tissue removed, total tumor excision is possible allowing detection of incidental associated lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Papilloma, Intraductal / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Hyperplasia. Mammary Glands, Human / pathology. Mammary Glands, Human / surgery. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878878.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down






Advertisement